{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:42:18Z","timestamp":1790653338524,"version":"4.1.0"},"reference-count":286,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"DOI":"10.1186\/s13048-025-01948-0","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T13:03:29Z","timestamp":1766149409000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["HPV-driven inflammatory pathways in ovarian carcinogenesis: molecular mechanisms and emerging therapeutic interventions"],"prefix":"10.1186","volume":"19","author":[{"given":"Atefeh Zamani","family":"Kermanshahi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Ebrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Taherpoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham Kamal","family":"Kazemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javid Sadri","family":"Nahand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahdat","family":"Poortahmasebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abolfazl","family":"Jafari-Sales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Bannazadeh Baghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"key":"1948_CR1","doi-asserted-by":"crossref","unstructured":"Liu C, Yin Q, Wu Z, Li W, Huang J, Chen B, Yang Y, Zheng X, Zeng L, Wang J. Inflammation and immune escape in ovarian cancer: pathways and therapeutic opportunities. J Inflamm Res. 2025;895\u2013909.","DOI":"10.2147\/JIR.S503479"},{"key":"1948_CR2","doi-asserted-by":"crossref","unstructured":"Capozzi VA, Incognito GG, Scarpelli E, Palumbo M, Randazzo CL, Pino A, Verde ML, Ronsini C, Riemma G, Gaiano M, Romeo P, Palmara V, Berretta R, Cianci S. Exploring the relationship between ovarian cancer and genital microbiota: a systematic review and meta-analysis. J Pers Med. 2024;14(4).","DOI":"10.3390\/jpm14040351"},{"key":"1948_CR3","unstructured":"Mandle HB. Pathogen recognition, inflammation, and ovarian cancer. Emory University; 2024."},{"issue":"1","key":"1948_CR4","doi-asserted-by":"publisher","first-page":"19935","DOI":"10.1038\/s41598-019-56448-1","volume":"9","author":"E Paradowska","year":"2019","unstructured":"Paradowska E, Jab\u0142o\u0144ska A, Studzi\u0144ska M, Wilczy\u0144ski M, Wilczy\u0144ski JR. Detection and genotyping of CMV and HPV in tumors and fallopian tubes from epithelial ovarian cancer patients. Sci Rep. 2019;9(1):19935.","journal-title":"Sci Rep"},{"issue":"16","key":"1948_CR5","doi-asserted-by":"publisher","first-page":"8754","DOI":"10.3390\/ijerph18168754","volume":"18","author":"J-Y Huang","year":"2021","unstructured":"Huang J-Y, Yang S-F, Wu P-J, Wang C-H, Tang C-H, Wang P-H. Different influences of endometriosis and pelvic inflammatory disease on the occurrence of ovarian cancer. Int J Environ Res Public Health. 2021;18(16):8754.","journal-title":"Int J Environ Res Public Health"},{"issue":"24","key":"1948_CR6","doi-asserted-by":"publisher","first-page":"16019","DOI":"10.3390\/ijms232416019","volume":"23","author":"M Cazzaniga","year":"2022","unstructured":"Cazzaniga M, Cardinali M, Di Pierro F, Bertuccioli A. Ovarian microbiota, ovarian cancer and the underestimated role of HPV. Int J Mol Sci. 2022;23(24):16019.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1948_CR7","doi-asserted-by":"publisher","first-page":"58","DOI":"10.30699\/ijmm.17.1.58","volume":"17","author":"A Jafari-Sales","year":"2023","unstructured":"Jafari-Sales A, Shariat A, Bannazadeh-Baghi H, Baradaran B, Jafari B. Human papillomavirus (HPV) prevalence and E6 protein expression in gastric cancer tissue samples compared with Non-malignant and control groups in East Azerbaijan Province, Iran, 2021. Iran J Med Microbiol. 2023;17(1):58\u201365.","journal-title":"Iran J Med Microbiol"},{"issue":"3","key":"1948_CR8","doi-asserted-by":"publisher","first-page":"413","DOI":"10.32604\/oncologie.2022.024161","volume":"24","author":"A Jafari-Sales","year":"2022","unstructured":"Jafari-Sales A, Shariat A, Baghi HB, Baradaran B, Jafari B. The presence of human papillomavirus and epstein-barr virus infection in gastric cancer: A systematic study. Oncologie. 2022;24(3):413\u201326.","journal-title":"Oncologie"},{"key":"1948_CR9","volume-title":"The effect of oncogene proteins of human papillomaviruses on apoptosis pathways in prostate cancer","author":"RF Baladehi","year":"2022","unstructured":"Baladehi RF, Memar MY, Sales AJ, Bazmani A, Nahand JS, Aghbash PS, Baghi HB. The effect of oncogene proteins of human papillomaviruses on apoptosis pathways in prostate cancer. Volume 24. Oncologie: Tech Science; 2022. 2."},{"issue":"1","key":"1948_CR10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13027-024-00624-0","volume":"19","author":"F Ebrahimi","year":"2024","unstructured":"Ebrahimi F, Rasizadeh R, Jafari S, Baghi HB. Prevalence of HPV in anal cancer: exploring the role of infection and inflammation. Infect Agents Cancer. 2024;19(1):63.","journal-title":"Infect Agents Cancer"},{"issue":"3","key":"1948_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.32604\/or.2022.026776","volume":"30","author":"PS Aghbash","year":"2023","unstructured":"Aghbash PS, Hemmat N, Baradaran B, Mokhtarzadeh A, Poortahmasebi V, Oskuee MA, Baghi HB. The effect of Wnt\/\u03b2-catenin signaling on PD-1\/PDL-1 axis in HPV-related cervical cancer. Oncol Res. 2023;30(3):99.","journal-title":"Oncol Res"},{"issue":"3","key":"1948_CR12","first-page":"e159690","volume":"22","author":"AJ Sales","year":"2025","unstructured":"Sales AJ, Hosseini-Karkaj K, Soleymanpour K, Kadkhodaei-Ilkhechi G, Farahnaki-Sadabadi M, Pashazadeh M. Human Papillomavirus Cerv Cancer: Narrative Rev Mod Care J. 2025;22(3):e159690.","journal-title":"Human Papillomavirus Cerv Cancer: Narrative Rev Mod Care J"},{"issue":"5","key":"1948_CR13","doi-asserted-by":"publisher","first-page":"ftz048","DOI":"10.1093\/femspd\/ftz048","volume":"77","author":"N Hemmat","year":"2019","unstructured":"Hemmat N, Bannazadeh H, Baghi. Association of human papillomavirus infection and inflammation in cervical cancer. Pathogens Disease. 2019;77(5):ftz048.","journal-title":"Pathogens Disease"},{"issue":"2","key":"1948_CR14","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/MRM.0000000000000261","volume":"33","author":"S Mahmoudi","year":"2022","unstructured":"Mahmoudi S, Jafari-Sales A, Nasiri R, Baghi HB. Prostate cancer and human papillomavirus infection: a recent literature review. Reviews Res Med Microbiol. 2022;33(2):100\u20138.","journal-title":"Reviews Res Med Microbiol"},{"issue":"1","key":"1948_CR15","doi-asserted-by":"publisher","first-page":"21602","DOI":"10.1038\/s41598-024-72814-0","volume":"14","author":"E Paradowska","year":"2024","unstructured":"Paradowska E, Har\u0119\u017ca DA, Kania KD, Jarych D, Wilczy\u0144ski M, Malinowski A, Kawecka M, Nowak M, Wilczy\u0144ski JR. Human papillomavirus infection of the fallopian tube as a potential risk factor for epithelial ovarian cancer. Sci Rep. 2024;14(1):21602.","journal-title":"Sci Rep"},{"issue":"6","key":"1948_CR16","doi-asserted-by":"publisher","first-page":"556","DOI":"10.3892\/ol.2024.14689","volume":"28","author":"TM Le","year":"2024","unstructured":"Le TM, Nguyen HDT, Cho J, Park NJY, Han HS, Chong GO, Seo I. Association of human papillomavirus 16 and 18 with ovarian cancer risk: insights from a meta\u2013analysis. Oncol Lett. 2024;28(6):556.","journal-title":"Oncol Lett"},{"issue":"17","key":"1948_CR17","doi-asserted-by":"publisher","first-page":"9408","DOI":"10.3390\/ijms25179408","volume":"25","author":"O Tarasova","year":"2024","unstructured":"Tarasova O, Petrou A, Ivanov SM, Geronikaki A, Poroikov V. Viral factors in modulation of host immune response: A route to novel antiviral agents and new therapeutic approaches. Int J Mol Sci. 2024;25(17):9408.","journal-title":"Int J Mol Sci"},{"key":"1948_CR18","doi-asserted-by":"publisher","first-page":"101339","DOI":"10.1016\/j.cegh.2023.101339","volume":"22","author":"B Fatima","year":"2023","unstructured":"Fatima B, Masud R, Sultana N, Javed A, Justin S. Detection of human papillomavirus in archival bladder and ovarian cancer samples. Clin Epidemiol Global Health. 2023;22:101339.","journal-title":"Clin Epidemiol Global Health"},{"issue":"6","key":"1948_CR19","first-page":"2959","volume":"17","author":"PP Zhang","year":"2016","unstructured":"Zhang PP, Zhou L, Cao JS, Li YP, Zeng Z, Sun N, Shen L, Zhu HY, Ruan Y, Zha WT, Wang XY, Zhang KQ, Zhang R. Possible epithelial ovarian cancer association with HPV18 or HPV33 infection. Asian Pac J Cancer Prev. 2016;17(6):2959\u201364.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"1948_CR20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13027-016-0087-4","volume":"11","author":"K Ingerslev","year":"2016","unstructured":"Ingerslev K, Hogdall E, Skovrider-Ruminski W, Schnack TH, Karlsen MA, Nedergaard L, Hogdall C, Blaak\u00e6r J. High-risk HPV is not associated with epithelial ovarian cancer in a Caucasian population. Infect Agents Cancer. 2016;11(1):39.","journal-title":"Infect Agents Cancer"},{"issue":"5","key":"1948_CR21","first-page":"1233","volume":"18","author":"F Farzaneh","year":"2017","unstructured":"Farzaneh F, Nadji SA, Khosravi D, Hosseini MS, Bahremani MH, Chehrazi M, Bagheri G, Sigaroodi A, Haghighatian Z. Lack of HPV in benign and malignant epithelial ovarian tumors in Iran. Asian Pac J Cancer Prevention: APJCP. 2017;18(5):1233.","journal-title":"Asian Pac J Cancer Prevention: APJCP"},{"issue":"2","key":"1948_CR22","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/07399330601128627","volume":"28","author":"S Konidaris","year":"2007","unstructured":"Konidaris S, Kouskouni EE, Panoskaltsis T, Kreatsas G, Patsouris ES, Sarivalassis A, Nonni A, Lazaris AC. Human papillomavirus infection in malignant and benign gynaecological conditions: a study in Greek women. Health Care Women Int. 2007;28(2):182\u201391.","journal-title":"Health Care Women Int"},{"issue":"4","key":"1948_CR23","first-page":"335","volume":"12","author":"M Hisada","year":"2001","unstructured":"Hisada M, Berg BJvd, Strickler HD, Christianson RE, Wright WE, Waters DJ, Rabkin CS. Prospective study of antibody to human papilloma virus type 16 and risk of cervical, endometrial, and ovarian cancers (United States). Cancer Causes Control. 2001;12(4):335\u201341.","journal-title":"Cancer Causes Control"},{"issue":"4","key":"1948_CR24","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3390\/jpm14040351","volume":"14","author":"VA Capozzi","year":"2024","unstructured":"Capozzi VA, Incognito GG, Scarpelli E, Palumbo M, Randazzo CL, Pino A, La Verde M, Ronsini C, Riemma G, Gaiano M. Exploring the relationship between ovarian cancer and genital microbiota: A systematic review and meta-analysis. J Personalized Med. 2024;14(4):351.","journal-title":"J Personalized Med"},{"issue":"6","key":"1948_CR25","first-page":"642","volume":"26","author":"E Kuscu","year":"2005","unstructured":"Kuscu E, Ozdemir BH, Erkanli S, Haberal A. HPV and p53 expression in epithelial ovarian carcinoma. Eur J Gynaecol Oncol. 2005;26(6):642\u20135.","journal-title":"Eur J Gynaecol Oncol"},{"issue":"8","key":"1948_CR26","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3390\/cancers10080251","volume":"10","author":"SS Savant","year":"2018","unstructured":"Savant SS, Sriramkumar S, O\u2019Hagan HM. The role of inflammation and inflammatory mediators in the Development, Progression, Metastasis, and chemoresistance of epithelial ovarian cancer. Cancers. 2018;10(8):251.","journal-title":"Cancers"},{"issue":"3","key":"1948_CR27","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/intimm\/dxaa078","volume":"33","author":"T Hirano","year":"2020","unstructured":"Hirano T. IL-6 in inflammation, autoimmunity and cancer. Int Immunol. 2020;33(3):127\u201348.","journal-title":"Int Immunol"},{"issue":"1","key":"1948_CR28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1479-5876-2-23","volume":"2","author":"RS Freedman","year":"2004","unstructured":"Freedman RS, Deavers M, Liu J, Wang E. Peritoneal inflammation \u2013 A microenvironment for epithelial ovarian cancer (EOC). J Translational Med. 2004;2(1):23.","journal-title":"J Translational Med"},{"issue":"1","key":"1948_CR29","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/aogs.12254","volume":"93","author":"MF Svahn","year":"2014","unstructured":"Svahn MF, Faber MT, Christensen J, Norrild B, Kjaer SK. Prevalence of human papillomavirus in epithelial ovarian cancer tissue. A meta-analysis of observational studies. Acta Obstet Gynecol Scand. 2014;93(1):6\u201319.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"1948_CR30","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.3389\/fimmu.2018.02160","volume":"9","author":"SC Gupta","year":"2018","unstructured":"Gupta SC, Kunnumakkara AB, Aggarwal S, Aggarwal BB. Inflammation, a double-edge sword for cancer and other age-related diseases. Front Immunol. 2018;9:2160.","journal-title":"Front Immunol"},{"issue":"4","key":"1948_CR31","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ccr.2007.10.005","volume":"12","author":"T Hagemann","year":"2007","unstructured":"Hagemann T, Balkwill F, Lawrence T. Inflammation and cancer: a double-edged sword. Cancer Cell. 2007;12(4):300\u20131.","journal-title":"Cancer Cell"},{"key":"1948_CR32","doi-asserted-by":"publisher","first-page":"1564572","DOI":"10.3389\/fonc.2025.1564572","volume":"15","author":"H Akk\u0131z","year":"2025","unstructured":"Akk\u0131z H, \u015eim\u015fek H, Balc\u0131 D, \u00dclger Y, Onan E, Ak\u00e7aer N, Delik A. Inflammation and cancer: molecular mechanisms and clinical consequences. Front Oncol. 2025;15:1564572.","journal-title":"Front Oncol"},{"issue":"7","key":"1948_CR33","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3390\/cells14070488","volume":"14","author":"A Nishida","year":"2025","unstructured":"Nishida A, Andoh A. The role of inflammation in cancer: mechanisms of tumor Initiation, Progression, and metastasis. Cells. 2025;14(7):488.","journal-title":"Cells"},{"key":"1948_CR34","doi-asserted-by":"crossref","unstructured":"Savant SS, Sriramkumar S, O\u2019Hagan HM. The role of inflammation and inflammatory mediators in the Development, Progression, Metastasis, and chemoresistance of epithelial ovarian cancer. Cancers (Basel). 2018;10(8).","DOI":"10.3390\/cancers10080251"},{"issue":"3","key":"1948_CR35","doi-asserted-by":"publisher","first-page":"121","DOI":"10.4103\/aam.aam_56_18","volume":"18","author":"N Singh","year":"2019","unstructured":"Singh N, Baby D, Rajguru JP, Patil PB, Thakkannavar SS, Pujari VB. Inflammation and cancer. Ann Afr Med. 2019;18(3):121\u20136.","journal-title":"Ann Afr Med"},{"issue":"6","key":"1948_CR36","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883\u201399.","journal-title":"Cell"},{"issue":"1","key":"1948_CR37","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40610-025-00167-2","volume":"11","author":"A Ghara","year":"2025","unstructured":"Ghara A, Matada GSP, Sah RK, Boneka SSSS, Paik A, Majumder S, Pramanick P, Metikurki B. Unravelling immunity: Understanding inflammatory pathways as key players in immune response and disease progression. Curr Mol Biology Rep. 2025;11(1):5.","journal-title":"Curr Mol Biology Rep"},{"issue":"9","key":"1948_CR38","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.3390\/ijms26094048","volume":"26","author":"D Potashnikova","year":"2025","unstructured":"Potashnikova D, Fasler-Kan E. Special issue functional role of cytokines in cancer and chronic inflammation. Int J Mol Sci. 2025;26(9):4048.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"1948_CR39","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1093\/carcin\/bgab075","volume":"42","author":"HE Sabaawy","year":"2021","unstructured":"Sabaawy HE, Ryan BM, Khiabanian H, Pine SR. JAK\/STAT of all trades: linking inflammation with cancer development, tumor progression and therapy resistance. Carcinogenesis. 2021;42(12):1411\u20139.","journal-title":"Carcinogenesis"},{"issue":"7","key":"1948_CR40","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/s41423-022-00877-y","volume":"19","author":"J Guo","year":"2022","unstructured":"Guo J, Xue Z, Wang L. Transcriptional regulation of the immune checkpoints PD-1 and CTLA-4. Cell Mol Immunol. 2022;19(7):861\u20132.","journal-title":"Cell Mol Immunol"},{"issue":"12","key":"1948_CR41","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1007\/s00011-023-01808-x","volume":"72","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Guo J, Jia R. Treg plasticity and human diseases. Inflamm Res. 2023;72(12):2181\u201397.","journal-title":"Inflamm Res"},{"issue":"10","key":"1948_CR42","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1093\/intimm\/dxp095","volume":"21","author":"S Sakaguchi","year":"2009","unstructured":"Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. Regulatory T cells: how do they suppress immune responses? Int Immunol. 2009;21(10):1105\u201311.","journal-title":"Int Immunol"},{"issue":"3","key":"1948_CR43","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1093\/cei\/uxac090","volume":"210","author":"NM de Gruijter","year":"2022","unstructured":"de Gruijter NM, Jebson B, Rosser EC. Cytokine production by human B cells: role in health and autoimmune disease. Clin Exp Immunol. 2022;210(3):253\u201362.","journal-title":"Clin Exp Immunol"},{"key":"1948_CR44","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3389\/fimmu.2018.00835","volume":"9","author":"K Hofmann","year":"2018","unstructured":"Hofmann K, Clauder A-K, Manz RA. Targeting B cells and plasma cells in autoimmune diseases. Front Immunol. 2018;9:835.","journal-title":"Front Immunol"},{"issue":"2","key":"1948_CR45","first-page":"310","volume":"11","author":"T Ma","year":"2022","unstructured":"Ma T, Renz BW, Ilmer M, Koch D, Yang Y, Werner J, Bazhin AV. Myeloid-Derived Suppressor Cells Solid Tumors Cells. 2022;11(2):310.","journal-title":"Myeloid-Derived Suppressor Cells Solid Tumors Cells"},{"issue":"1","key":"1948_CR46","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1007\/s12672-025-02971-9","volume":"16","author":"Y-Y Liu","year":"2025","unstructured":"Liu Y-Y, Ohashi Y, Ushijima T. How chronic inflammation fuels carcinogenesis as an environmental epimutagen. Discover Oncol. 2025;16(1):1150.","journal-title":"Discover Oncol"},{"issue":"1","key":"1948_CR47","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13045-024-01654-2","volume":"18","author":"Y Duan","year":"2025","unstructured":"Duan Y, Xu Y, Dou Y, Xu D. Helicobacter pylori and gastric cancer: mechanisms and new perspectives. J Hematol Oncol. 2025;18(1):10.","journal-title":"J Hematol Oncol"},{"key":"1948_CR48","unstructured":"Liu Y, Yu Y, Chen Y, Zhuang J, Sun C. Tumor Immunosenescence driven by chronic inflammation: mechanisms, microenvironment remodeling and therapeutic strategies. Aging Disease. 2025;0."},{"issue":"11","key":"1948_CR49","doi-asserted-by":"publisher","first-page":"5421","DOI":"10.3390\/ijms22115421","volume":"22","author":"S Hibino","year":"2021","unstructured":"Hibino S, Kawazoe T, Kasahara H, Itoh S, Ishimoto T, Sakata-Yanagimoto M, Taniguchi K. Inflammation-Induced tumorigenesis and metastasis. Int J Mol Sci. 2021;22(11):5421.","journal-title":"Int J Mol Sci"},{"key":"1948_CR50","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.3389\/fonc.2019.01399","volume":"9","author":"D Aguilar-Cazares","year":"2019","unstructured":"Aguilar-Cazares D, Chavez-Dominguez R, Carlos-Reyes A, Lopez-Camarillo C, Hernadez ON, de la Cruz, Lopez-Gonzalez JS. Contribution of angiogenesis to inflammation and cancer. Front Oncol. 2019;9:1399.","journal-title":"Front Oncol"},{"key":"1948_CR51","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3389\/fimmu.2011.00098","volume":"2","author":"G Multhoff","year":"2012","unstructured":"Multhoff G, Molls M, Radons J. Chronic inflammation in cancer development. Front Immunol. 2012;2:98.","journal-title":"Front Immunol"},{"key":"1948_CR52","doi-asserted-by":"publisher","first-page":"113625","DOI":"10.1016\/j.intimp.2024.113625","volume":"145","author":"PS Aghbash","year":"2025","unstructured":"Aghbash PS, Rasizadeh R, Nahand JS, Baghi HB. The role of immune cells and inflammasomes in modulating cytokine responses in HPV-Related cervical cancer. Int Immunopharmacol. 2025;145:113625.","journal-title":"Int Immunopharmacol"},{"key":"1948_CR53","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.3389\/fimmu.2020.01513","volume":"11","author":"JA Soto","year":"2020","unstructured":"Soto JA, G\u00e1lvez NM, Andrade CA, Pacheco GA, Bohmwald K, Berrios RV, Bueno SM, Kalergis AM. The role of dendritic cells during infections caused by highly prevalent viruses. Front Immunol. 2020;11:1513.","journal-title":"Front Immunol"},{"issue":"10","key":"1948_CR54","first-page":"849","volume":"21","author":"M Zhang","year":"2024","unstructured":"Zhang M, Qin H, Wu Y, Gao Q. Complex role of neutrophils in the tumor microenvironment: an avenue for novel immunotherapies. Cancer Biol Med. 2024;21(10):849\u201363.","journal-title":"Cancer Biol Med"},{"key":"1948_CR55","doi-asserted-by":"publisher","first-page":"721","DOI":"10.3332\/ecancer.2017.721","volume":"11","author":"TG Shrihari","year":"2017","unstructured":"Shrihari TG. Dual role of inflammatory mediators in cancer. Ecancermedicalscience. 2017;11:721.","journal-title":"Ecancermedicalscience"},{"key":"1948_CR56","doi-asserted-by":"crossref","unstructured":"Mantovani A, Ponzetta A, Inforzato A, Jaillon S. Innate immunity, inflammation and tumour progression: double-edged swords. Wiley Online Library; 2019. p. 524\u2013532.","DOI":"10.1111\/joim.12886"},{"key":"1948_CR57","doi-asserted-by":"publisher","first-page":"6058147","DOI":"10.1155\/2016\/6058147","volume":"2016","author":"J Kim","year":"2016","unstructured":"Kim J, Bae JS. Tumor-associated macrophages and neutrophils in tumor microenvironment. Mediators Inflamm. 2016;2016:6058147.","journal-title":"Mediators Inflamm"},{"issue":"9","key":"1948_CR58","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.3390\/cancers14092220","volume":"14","author":"D Schweer","year":"2022","unstructured":"Schweer D, McAtee A, Neupane K, Richards C, Ueland F, Kolesar J. Tumor-Associated macrophages and ovarian cancer: implications for therapy. Cancers. 2022;14(9):2220.","journal-title":"Cancers"},{"key":"1948_CR59","doi-asserted-by":"publisher","first-page":"696605","DOI":"10.3389\/fimmu.2021.696605","volume":"12","author":"Z Su","year":"2021","unstructured":"Su Z, Tao X. Current Understanding of IL-37 in human health and disease. Front Immunol. 2021;12:696605.","journal-title":"Front Immunol"},{"key":"1948_CR60","doi-asserted-by":"publisher","first-page":"155760","DOI":"10.1016\/j.cyto.2021.155760","volume":"150","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Qin H, Ye K, Sun C, Qin Y, Li G, Wang H, Wang H. Dual role of IL-37 in the progression of tumors. Cytokine. 2022;150:155760.","journal-title":"Cytokine"},{"key":"1948_CR61","doi-asserted-by":"publisher","first-page":"1278521","DOI":"10.3389\/fimmu.2023.1278521","volume":"14","author":"M Gu","year":"2023","unstructured":"Gu M, Jin Y, Gao X, Xia W, Xu T, Pan S. Novel insights into IL-37: an anti-inflammatory cytokine with emerging roles in anti-cancer process. Front Immunol. 2023;14:1278521.","journal-title":"Front Immunol"},{"issue":"2","key":"1948_CR62","first-page":"e1151","volume":"2","author":"Y Mei","year":"2019","unstructured":"Mei Y, Liu H. IL-37: an anti-inflammatory cytokine with antitumor functions. Cancer Rep (Hoboken). 2019;2(2):e1151.","journal-title":"Cancer Rep (Hoboken)"},{"key":"1948_CR63","doi-asserted-by":"crossref","unstructured":"Christodoulou P, Kyriakou TC, Boutsikos P, Andreou M, Ji Y, Xu D, Papageorgis P, Christodoulou MI. Aberrant expression and prognostic potential of IL-37 in human lung adenocarcinoma. Biomedicines. 2022;10(12).","DOI":"10.3390\/biomedicines10123037"},{"issue":"1","key":"1948_CR64","doi-asserted-by":"publisher","first-page":"2297504","DOI":"10.1080\/2162402X.2023.2297504","volume":"13","author":"N Landolina","year":"2024","unstructured":"Landolina N, Mariotti FR, Pelosi A, D\u2019Oria V, Ingegnere T, Alicata C, Vacca P, Moretta L, Maggi E. The anti-inflammatory cytokine IL-37 improves the NK cell-mediated anti-tumor response. Oncoimmunology. 2024;13(1):2297504.","journal-title":"Oncoimmunology"},{"key":"1948_CR65","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.semcancer.2019.07.013","volume":"66","author":"L Emdad","year":"2020","unstructured":"Emdad L, Bhoopathi P, Talukdar S, Pradhan AK, Sarkar D, Wang XY, Das SK, Fisher PB. Recent insights into apoptosis and toxic autophagy: the roles of MDA-7\/IL-24, a multidimensional anti-cancer therapeutic. Semin Cancer Biol. 2020;66:140\u201354.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"1948_CR66","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3390\/ijms23010072","volume":"23","author":"J Modi","year":"2022","unstructured":"Modi J, Roy A, Pradhan AK, Kumar A, Talukdar S, Bhoopathi P, Maji S, Mannangatti P, De La Rosa DS, Li J, Guo C, Subler MA, Windle JJ, Cavenee WK, Sarkar D, Wang X-Y, Das SK, Emdad L, Fisher PB. Insights into the mechanisms of action of MDA-7\/IL-24: A ubiquitous Cancer-Suppressing protein. Int J Mol Sci. 2022;23(1):72.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"1948_CR67","doi-asserted-by":"publisher","first-page":"581","DOI":"10.3109\/07853890.2011.595732","volume":"43","author":"G Germano","year":"2011","unstructured":"Germano G, Mantovani A, Allavena P. Targeting of the innate immunity\/inflammation as complementary anti-tumor therapies. Ann Med. 2011;43(8):581\u201393.","journal-title":"Ann Med"},{"issue":"5","key":"1948_CR68","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1007\/s13224-023-01751-1","volume":"73","author":"S Gupte","year":"2023","unstructured":"Gupte S, Parthasarathy S, Arora P, Ozalkar S, Jangam S, Rajwade K, Nikam P, Shah S. A Rapid, sensitive and Type-Specific detection of High-Risk HPV-16 and HPV-18. J Obstet Gynaecol India. 2023;73(5):440\u20134.","journal-title":"J Obstet Gynaecol India"},{"key":"1948_CR69","doi-asserted-by":"publisher","first-page":"148904","DOI":"10.1016\/j.gene.2024.148904","volume":"932","author":"R Rasizadeh","year":"2025","unstructured":"Rasizadeh R, Aghbash PS, Mokhtarzadeh A, Poortahmasebi V, Oskouee MA, Nahand JS, Amini M, Mahdavi SZB, Yari AH, Baghi HB. Novel strategies in HPV\u201316\u2013related cervical cancer treatment: an in vitro study of combined siRNA-E5 with oxaliplatin and Ifosfamide chemotherapy. Gene. 2025;932:148904.","journal-title":"Gene"},{"issue":"1","key":"1948_CR70","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40001-023-01014-9","volume":"28","author":"P Shiri Aghbash","year":"2023","unstructured":"Shiri Aghbash P, Hemmat N, Baradaran B, Bannazadeh Baghi H. siRNA-E6 sensitizes HPV-16-related cervical cancer through oxaliplatin: an in vitro study on anti-cancer combination therapy. Eur J Med Res. 2023;28(1):42.","journal-title":"Eur J Med Res"},{"issue":"6","key":"1948_CR71","doi-asserted-by":"publisher","first-page":"556","DOI":"10.3892\/ol.2024.14689","volume":"28","author":"TM Le","year":"2024","unstructured":"Le TM, Nguyen HDT, Cho J, Park NJ, Han HS, Chong GO, Seo I. Association of human papillomavirus 16 and 18 with ovarian cancer risk: insights from a meta\u2013analysis. Oncol Lett. 2024;28(6):556.","journal-title":"Oncol Lett"},{"key":"1948_CR72","doi-asserted-by":"crossref","unstructured":"Har\u0119\u017ca DA, Wilczy\u0144ski JR, Paradowska E. Human papillomaviruses as infectious agents in gynecological Cancers. Oncogenic properties of viral proteins. Int J Mol Sci. 2022;23(3).","DOI":"10.3390\/ijms23031818"},{"key":"1948_CR73","doi-asserted-by":"publisher","first-page":"104721","DOI":"10.1016\/j.critrevonc.2025.104721","volume":"211","author":"V Ranasinghe","year":"2025","unstructured":"Ranasinghe V, McMillan N. Novel therapeutic strategies for targeting E6 and E7 oncoproteins in cervical cancer. Crit Rev Oncol Hematol. 2025;211:104721.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"1948_CR74","doi-asserted-by":"crossref","first-page":"11","DOI":"10.21641\/los.15.1.58","volume":"15","author":"P Sen","year":"2018","unstructured":"Sen P, Ganguly P, Ganguly N. Modulation of DNA methylation by human papillomavirus E6 and E7 oncoproteins in cervical cancer. Oncol Lett. 2018;15(1):11\u201322.","journal-title":"Oncol Lett"},{"issue":"4","key":"1948_CR75","doi-asserted-by":"publisher","first-page":"864","DOI":"10.20892\/j.issn.2095-3941.2020.0370","volume":"17","author":"KA Szymonowicz","year":"2020","unstructured":"Szymonowicz KA, Chen J. Biological and clinical aspects of HPV-related cancers. Cancer Biol Med. 2020;17(4):864\u201378.","journal-title":"Cancer Biol Med"},{"key":"1948_CR76","doi-asserted-by":"crossref","unstructured":"Porter VL, Marra MA. The drivers, mechanisms, and consequences of genome instability in HPV-driven cancers. Cancers (Basel). 2022;14(19).","DOI":"10.3390\/cancers14194623"},{"key":"1948_CR77","unstructured":"Song Y, Gui C, Xian Q, Lv N, Ji M, Zhou Y. Previously undescribed effects and mechanisms of STAT3 in HPV-induced DNA re-replication in response to DNA damage. Febs J. 2025."},{"issue":"5","key":"1948_CR78","first-page":"e0072924","volume":"15","author":"L Yu","year":"2024","unstructured":"Yu L, Majerciak V, Lobanov A, Mirza S, Band V, Liu H, Cam M, Hughes SH, Lowy DR, Zheng ZM. HPV Oncogenes Expressed only One Multiple Integr HPV DNA Copies Drive Clonal Cell Expansion Cerv Cancer mBio. 2024;15(5):e0072924.","journal-title":"HPV Oncogenes Expressed only One Multiple Integr HPV DNA Copies Drive Clonal Cell Expansion Cerv Cancer mBio"},{"issue":"1","key":"1948_CR79","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1186\/s12967-025-06470-x","volume":"23","author":"SK Baba","year":"2025","unstructured":"Baba SK, Alblooshi SSE, Yaqoob R, Behl S, Al Saleem M, Rakha EA, Malik F, Singh M, Macha MA, Akhtar MK, Houry WA, Bhat AA, Al Menhali A, Zheng ZM, Mirza S. Human papilloma virus (HPV) mediated cancers: an insightful update. J Transl Med. 2025;23(1):483.","journal-title":"J Transl Med"},{"key":"1948_CR80","doi-asserted-by":"publisher","first-page":"p5315816","DOI":"10.1155\/2018\/5315816","volume":"2018","author":"SR Georgescu","year":"2018","unstructured":"Georgescu SR, Mitran CI, Mitran MI, Caruntu C, Sarbu MI, Matei C, Nicolae I, Tocut SM, Popa MI, Tampa M. New insights in the pathogenesis of HPV infection and the associated carcinogenic processes: the role of chronic inflammation and oxidative stress. J Immunol Res. 2018;2018:p5315816.","journal-title":"J Immunol Res"},{"key":"1948_CR81","doi-asserted-by":"publisher","first-page":"102462","DOI":"10.1016\/j.tranon.2025.102462","volume":"59","author":"O Gultekin","year":"2025","unstructured":"Gultekin O, Gonzalez-Molina J, Sarhan D, Groes-Kofoed N, Hassan MU, Lehti K, Salehi S. Systemic and tumor-specific inflammatory markers VCAM-1 and ICAM-1 as indicators of extent of surgery and oncologic outcome in advanced ovarian cancer. Transl Oncol. 2025;59:102462.","journal-title":"Transl Oncol"},{"issue":"4","key":"1948_CR82","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1172\/JCI129497","volume":"130","author":"X Luo","year":"2020","unstructured":"Luo X, Donnelly CR, Gong W, Heath BR, Hao Y, Donnelly LA, Moghbeli T, Tan YS, Lin X, Bellile E, Kansy BA, Carey TE, Brenner JC, Cheng L, Polverini PJ, Morgan MA, Wen H, Prince ME, Ferris RL, Xie Y, et al. HPV16 drives cancer immune escape via NLRX1-mediated degradation of STING. J Clin Invest. 2020;130(4):1635\u201352.","journal-title":"J Clin Invest"},{"issue":"2","key":"1948_CR83","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/ijc.31027","volume":"142","author":"A Steinbach","year":"2018","unstructured":"Steinbach A, Riemer AB. Immune evasion mechanisms of human papillomavirus: an update. Int J Cancer. 2018;142(2):224\u20139.","journal-title":"Int J Cancer"},{"issue":"1","key":"1948_CR84","doi-asserted-by":"publisher","first-page":"28","DOI":"10.4103\/tcmj.tcmj_134_24","volume":"37","author":"MM Mohammed","year":"2025","unstructured":"Mohammed MM, Al-Khafaji ZAI, Al-Hilli NM. An exploration of the natural and acquired immunological mechanisms to high-risk human papillomavirus infection and unmasking immune escape in cervical cancer: A concise synopsis. Tzu Chi Med J. 2025;37(1):28\u201341.","journal-title":"Tzu Chi Med J"},{"issue":"5","key":"1948_CR85","doi-asserted-by":"publisher","first-page":"e0192523","DOI":"10.1128\/jvi.01925-23","volume":"98","author":"L Chen","year":"2024","unstructured":"Chen L, Hu H, Pan Y, Lu Y, Zhao M, Zhao Y, Wang L, Liu K, Yu Z. The role of HPV11 E7 in modulating STING-dependent interferon \u03b2 response in recurrent respiratory papillomatosis. J Virol. 2024;98(5):e0192523.","journal-title":"J Virol"},{"key":"1948_CR86","doi-asserted-by":"crossref","unstructured":"Castro-Mu\u00f1oz LJ, Rocha-Zavaleta L, Lizano M, Ram\u00edrez-Alc\u00e1ntara KM, Madrid-Marina V, Manzo-Merino J. Alteration of the IFN-Pathway by human papillomavirus proteins: antiviral immune response evasion mechanism. Biomedicines. 2022;10(11).","DOI":"10.3390\/biomedicines10112965"},{"issue":"8","key":"1948_CR87","doi-asserted-by":"publisher","first-page":"5101","DOI":"10.1007\/s10238-023-01165-3","volume":"23","author":"MR Ambrosio","year":"2023","unstructured":"Ambrosio MR, Niccolai E, Petrelli F, Di Gloria L, Bertacca G, Giusti A, Baldi S, Cavazzana A, Palmeri M, Perotti B, Ramazzotti M, Arganini M, Amedei A. Immune landscape and oncobiota in HPV-Associated colorectal cancer: an explorative study. Clin Exp Med. 2023;23(8):5101\u201312.","journal-title":"Clin Exp Med"},{"issue":"2","key":"1948_CR88","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/jmv.25312","volume":"91","author":"CM Bonin","year":"2019","unstructured":"Bonin CM, Padovani CTJ, da Costa IP, \u00c1vila LS, Ferreira AMT, Fernandes CES, Dos AR, Santos, Tozetti IA. Detection of regulatory T cell phenotypic markers and cytokines in patients with human papillomavirus infection. J Med Virol. 2019;91(2):317\u201325.","journal-title":"J Med Virol"},{"key":"1948_CR89","doi-asserted-by":"publisher","first-page":"1586806","DOI":"10.3389\/fimmu.2025.1586806","volume":"16","author":"Z Chen","year":"2025","unstructured":"Chen Z, Zhao B. The role of tumor-associated macrophages in HPV induced cervical cancer. Front Immunol. 2025;16:1586806.","journal-title":"Front Immunol"},{"key":"1948_CR90","doi-asserted-by":"publisher","first-page":"42929","DOI":"10.1038\/srep42929","volume":"7","author":"S Aust","year":"2017","unstructured":"Aust S, Felix S, Auer K, Bachmayr-Heyda A, Kenner L, Dekan S, Meier SM, Gerner C, Grimm C, Pils D. Absence of PD-L1 on tumor cells is associated with reduced MHC I expression and PD-L1 expression increases in recurrent serous ovarian cancer. Sci Rep. 2017;7:42929.","journal-title":"Sci Rep"},{"key":"1948_CR91","doi-asserted-by":"publisher","first-page":"1328651","DOI":"10.3389\/fimmu.2023.1328651","volume":"14","author":"F Blanc-Durand","year":"2023","unstructured":"Blanc-Durand F, Clemence Wei L, Xian, Tan DSP. Targeting the immune microenvironment for ovarian cancer therapy. Front Immunol. 2023;14:1328651.","journal-title":"Front Immunol"},{"key":"1948_CR92","doi-asserted-by":"crossref","unstructured":"Folliero V, Dell\u2019Annunziata F, Chianese A, Morone MV, Mensitieri F, Di Spirito F, Mollo A, Amato M, Galdiero M, Dal Piaz F, Pagliano P, Rinaldi L, Franci G. Epigenetic and genetic keys to fight HPV-related cancers. Cancers (Basel). 2023;15(23).","DOI":"10.3390\/cancers15235583"},{"key":"1948_CR93","doi-asserted-by":"crossref","unstructured":"Pavelescu LA, Mititelu-Zafiu NL, Mindru DE, Vladareanu R, Curici A. Molecular insights into HPV-Driven cervical cancer: oncoproteins, immune evasion, and epigenetic modifications. Microorganisms. 2025;13(5).","DOI":"10.3390\/microorganisms13051000"},{"issue":"1","key":"1948_CR94","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s10020-021-00295-2","volume":"27","author":"A Sipos","year":"2021","unstructured":"Sipos A, Ujlaki G, Mik\u00f3 E, Maka E, Szab\u00f3 J, Uray K, Krasznai Z, Bai P. The role of the Microbiome in ovarian cancer: mechanistic insights into oncobiosis and to bacterial metabolite signaling. Mol Med. 2021;27(1):33.","journal-title":"Mol Med"},{"key":"1948_CR95","doi-asserted-by":"crossref","unstructured":"Cazzaniga M, Cardinali M, Di Pierro F, Bertuccioli A. Ovarian microbiota, ovarian cancer and the underestimated role of HPV. Int J Mol Sci. 2022;23(24).","DOI":"10.3390\/ijms232416019"},{"issue":"1","key":"1948_CR96","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1038\/s41467-022-28724-8","volume":"13","author":"A Lebeau","year":"2022","unstructured":"Lebeau A, Bruyere D, Roncarati P, Peixoto P, Hervouet E, Cobraiville G, Taminiau B, Masson M, Gallego C, Mazzucchelli G, Smargiasso N, Fleron M, Baiwir D, Hendrick E, Pilard C, Lerho T, Reynders C, Ancion M, Greimers R, Twizere JC, et al. HPV infection alters vaginal Microbiome through down-regulating host mucosal innate peptides used by lactobacilli as amino acid sources. Nat Commun. 2022;13(1):1076.","journal-title":"Nat Commun"},{"key":"1948_CR97","doi-asserted-by":"crossref","unstructured":"Papamentzelopoulou M, Pitiriga VC. Unlocking the interactions between the whole-body microbiome and HPV infection: a literature review. Pathogens. 2025;14(3).","DOI":"10.3390\/pathogens14030293"},{"key":"1948_CR98","doi-asserted-by":"crossref","unstructured":"Jain M, Yadav D, Jarouliya U, Chavda V, Yadav AK, Chaurasia B, Song M. Epidemiology, molecular pathogenesis, Immuno-Pathogenesis, immune escape mechanisms and vaccine evaluation for HPV-associated carcinogenesis. Pathogens. 2023;12(12).","DOI":"10.3390\/pathogens12121380"},{"issue":"8","key":"1948_CR99","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1158\/2159-8290.CD-20-1760","volume":"11","author":"AA Shamseddine","year":"2021","unstructured":"Shamseddine AA, Burman B, Lee NY, Zamarin D, Riaz N. Tumor immunity and immunotherapy for HPV-Related cancers. Cancer Discov. 2021;11(8):1896\u2013912.","journal-title":"Cancer Discov"},{"issue":"6","key":"1948_CR100","doi-asserted-by":"publisher","first-page":"e29685","DOI":"10.1002\/jmv.29685","volume":"96","author":"I Lo Cigno","year":"2024","unstructured":"Lo Cigno I, Calati F, Girone C, Catozzo M, Gariglio M. High-risk HPV oncoproteins E6 and E7 and their interplay with the innate immune response: Uncovering mechanisms of immune evasion and therapeutic prospects. J Med Virol. 2024;96(6):e29685.","journal-title":"J Med Virol"},{"key":"1948_CR101","doi-asserted-by":"publisher","first-page":"p629350","DOI":"10.3389\/fonc.2021.629350","volume":"11","author":"X Chen","year":"2021","unstructured":"Chen X, He H, Xiao Y, Hasim A, Yuan J, Ye M, Li X, Hao Y, Guo X. CXCL10 produced by HPV-Positive cervical cancer cells stimulates Exosomal PDL1 expression by fibroblasts via CXCR3 and JAK-STAT pathways. Front Oncol. 2021;11:p629350.","journal-title":"Front Oncol"},{"issue":"1","key":"1948_CR102","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s12943-024-02095-8","volume":"23","author":"Q Liu","year":"2024","unstructured":"Liu Q, Guan Y, Li S. Programmed death receptor (PD-)1\/PD-ligand (L)1 in urological cancers: the all-around warrior in immunotherapy. Mol Cancer. 2024;23(1):183.","journal-title":"Mol Cancer"},{"issue":"2","key":"1948_CR103","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3233\/CBM-170357","volume":"21","author":"D Tan","year":"2018","unstructured":"Tan D, Sheng L, Yi QH. Correlation of PD-1\/PD-L1 polymorphisms and expressions with clinicopathologic features and prognosis of ovarian cancer. Cancer Biomark. 2018;21(2):287\u201397.","journal-title":"Cancer Biomark"},{"key":"1948_CR104","doi-asserted-by":"crossref","unstructured":"Cornel AM, Mimpen IL, Nierkens S. MHC class I downregulation in cancer: underlying mechanisms and potential targets for cancer immunotherapy. Cancers (Basel). 2020;12(7).","DOI":"10.3390\/cancers12071760"},{"key":"1948_CR105","doi-asserted-by":"crossref","unstructured":"Gameiro SF, Zhang A, Ghasemi F, Barrett JW, Nichols AC, Mymryk JS. Analysis of class I major histocompatibility complex gene transcription in human tumors caused by human papillomavirus infection. Viruses. 2017;9(9).","DOI":"10.3390\/v9090252"},{"key":"1948_CR106","doi-asserted-by":"crossref","unstructured":"Scarth JA, Patterson MR, Morgan EL, Macdonald A. The human papillomavirus oncoproteins: a review of the host pathways targeted on the road to transformation. J Gen Virol. 2021;102(3).","DOI":"10.1099\/jgv.0.001540"},{"key":"1948_CR107","doi-asserted-by":"crossref","unstructured":"Hensler M, Kasikova L, Fiser K, Rakova J, Skapa P, Laco J, Lanickova T, Pecen L, Truxova I, Vosahlikova S, Moserova I, Praznovec I, Drochytek V, Rehackova M, Brtnicky T, Rob L, Benes V, Pistolic J, Sojka L, Ryska A et al. M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer. J Immunother Cancer. 2020;8(2).","DOI":"10.1136\/jitc-2020-000979"},{"key":"1948_CR108","doi-asserted-by":"crossref","unstructured":"Ok\u0142a K. Myeloid-derived suppressor cells (MDSCs) in ovarian cancer-looking back and forward. Cells. 2023;12(14).","DOI":"10.3390\/cells12141912"},{"key":"1948_CR109","doi-asserted-by":"crossref","unstructured":"Haist M, Stege H, Grabbe S, Bros M. The functional crosstalk between myeloid-derived suppressor cells and regulatory T cells within the immunosuppressive tumor microenvironment. Cancers (Basel). 2021;13(2).","DOI":"10.3390\/cancers13020210"},{"key":"1948_CR110","doi-asserted-by":"publisher","first-page":"1631226","DOI":"10.3389\/fimmu.2025.1631226","volume":"16","author":"J Li","year":"2025","unstructured":"Li J, Huang H, Xie R, Yang R, Wang H, Wan L. Immunosuppressive mechanisms and therapeutic targeting of regulatory T cells in ovarian cancer. Front Immunol. 2025;16:1631226.","journal-title":"Front Immunol"},{"key":"1948_CR111","doi-asserted-by":"crossref","unstructured":"Cassar E, Kartikasari AER, Plebanski M. Regulatory T Cells in Ovarian Carcinogenesis and Future Therapeutic Opportunities. Cancers (Basel). 2022;14(22).","DOI":"10.3390\/cancers14225488"},{"issue":"7","key":"1948_CR112","doi-asserted-by":"publisher","first-page":"e0133681","DOI":"10.1371\/journal.pone.0133681","volume":"10","author":"X Liu","year":"2015","unstructured":"Liu X, Ma X, Lei Z, Feng H, Wang S, Cen X, Gao S, Jiang Y, Jiang J, Chen Q, Tang Y, Tang Y, Liang X. Chronic Inflammation-Related HPV: A driving force speeds oropharyngeal carcinogenesis. PLoS ONE. 2015;10(7):e0133681.","journal-title":"PLoS ONE"},{"key":"1948_CR113","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.2147\/OTT.S278089","volume":"14","author":"DB Sacdalan","year":"2021","unstructured":"Sacdalan DB, Lucero JA. The association between inflammation and immunosuppression: implications for ICI biomarker development. Onco Targets Ther. 2021;14:2053\u201364.","journal-title":"Onco Targets Ther"},{"key":"1948_CR114","doi-asserted-by":"publisher","first-page":"p2606928","DOI":"10.1155\/2022\/2606928","volume":"2022","author":"W Yu","year":"2022","unstructured":"Yu W, Tu Y, Long Z, Liu J, Kong D, Peng J, Wu H, Zheng G, Zhao J, Chen Y, Liu R, Li W, Hai C. Reactive oxygen species Bridge the gap between chronic inflammation and tumor development. Oxid Med Cell Longev. 2022;2022:p2606928.","journal-title":"Oxid Med Cell Longev"},{"key":"1948_CR115","first-page":"107","volume":"421","author":"O Sokolova","year":"2019","unstructured":"Sokolova O, Naumann M. Crosstalk between DNA damage and inflammation in the multiple steps of gastric carcinogenesis. Curr Top Microbiol Immunol. 2019;421:107\u201337.","journal-title":"Curr Top Microbiol Immunol"},{"issue":"11","key":"1948_CR116","doi-asserted-by":"publisher","first-page":"e1009028","DOI":"10.1371\/journal.ppat.1009028","volume":"16","author":"BL Uhlorn","year":"2020","unstructured":"Uhlorn BL, Jackson R, Li S, Bratton SM, Van Doorslaer K, Campos SK. Vesicular trafficking permits evasion of cGAS\/STING surveillance during initial human papillomavirus infection. PLoS Pathog. 2020;16(11):e1009028.","journal-title":"PLoS Pathog"},{"issue":"1","key":"1948_CR117","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1186\/s12967-025-06843-2","volume":"23","author":"Z Huang","year":"2025","unstructured":"Huang Z, Zhu J, Zhou YL, Shi J. The cGAS-STING pathway: a dual regulator of immune response in cancer and therapeutic implications. J Transl Med. 2025;23(1):766.","journal-title":"J Transl Med"},{"key":"1948_CR118","doi-asserted-by":"publisher","first-page":"1407649","DOI":"10.3389\/fimmu.2024.1407649","volume":"15","author":"SY Qi","year":"2024","unstructured":"Qi SY, Yang MM, Li CY, Yu K, Deng SL. The HPV viral regulatory mechanism of TLRs and the related treatments for HPV-associated cancers. Front Immunol. 2024;15:1407649.","journal-title":"Front Immunol"},{"key":"1948_CR119","doi-asserted-by":"publisher","first-page":"p2912671","DOI":"10.1155\/2018\/2912671","volume":"2018","author":"MR Barros Jr","year":"2018","unstructured":"Barros MR Jr., de Oliveira THA, de Melo CML, Venuti A, de Freitas AC. Viral modulation of TLRs and cytokines and the related immunotherapies for HPV-Associated cancers. J Immunol Res. 2018;2018:p2912671.","journal-title":"J Immunol Res"},{"issue":"1","key":"1948_CR120","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s13046-022-02481-4","volume":"41","author":"A Tosi","year":"2022","unstructured":"Tosi A, Parisatto B, Menegaldo A, Spinato G, Guido M, Del Mistro A, Bussani R, Zanconati F, Tofanelli M, Tirelli G, Boscolo-Rizzo P, Rosato A. The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and Spatial analysis unveils a rationale to target treatment-na\u00efve tumors with immune checkpoint inhibitors. J Exp Clin Cancer Res. 2022;41(1):279.","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"1948_CR121","first-page":"451","volume":"21","author":"X Kong","year":"2024","unstructured":"Kong X, Zhang J, Chen S, Wang X, Xi Q, Shen H, Zhang R. Immune checkpoint inhibitors: breakthroughs in cancer treatment. Cancer Biol Med. 2024;21(6):451\u201372.","journal-title":"Cancer Biol Med"},{"issue":"10","key":"1948_CR122","doi-asserted-by":"publisher","first-page":"e1498439","DOI":"10.1080\/2162402X.2018.1498439","volume":"7","author":"SF Gameiro","year":"2018","unstructured":"Gameiro SF, Ghasemi F, Barrett JW, Koropatnick J, Nichols AC, Mymryk JS, Maleki V. Treatment-na\u00efve HPV\u2009+\u2009head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy. Oncoimmunology. 2018;7(10):e1498439.","journal-title":"Oncoimmunology"},{"issue":"12","key":"1948_CR123","doi-asserted-by":"publisher","first-page":"3831","DOI":"10.3390\/v4123831","volume":"4","author":"CH Yuan","year":"2012","unstructured":"Yuan CH, Filippova M, Duerksen-Hughes P. Modulation of apoptotic pathways by human papillomaviruses (HPV): mechanisms and implications for therapy. Viruses. 2012;4(12):3831\u201350.","journal-title":"Viruses"},{"key":"1948_CR124","doi-asserted-by":"crossref","unstructured":"Morgan EL, Macdonald A. Manipulation of JAK\/STAT signalling by High-Risk hpvs: potential therapeutic targets for HPV-associated malignancies. Viruses. 2020;12(9).","DOI":"10.3390\/v12090977"},{"key":"1948_CR125","doi-asserted-by":"crossref","unstructured":"Bule P, Aguiar SI, Aires-Da-Silva F, Dias JNR. Chemokine-directed tumor microenvironment modulation in cancer immunotherapy. Int J Mol Sci. 2021;22(18).","DOI":"10.3390\/ijms22189804"},{"issue":"16","key":"1948_CR126","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","volume":"30","author":"NM Anderson","year":"2020","unstructured":"Anderson NM, Simon MC. The tumor microenvironment. Curr Biol. 2020;30(16):R921\u20135.","journal-title":"Curr Biol"},{"issue":"7","key":"1948_CR127","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1089\/ars.2012.5149","volume":"20","author":"M Mittal","year":"2014","unstructured":"Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive oxygen species in inflammation and tissue injury. Antioxid Redox Signal. 2014;20(7):1126\u201367.","journal-title":"Antioxid Redox Signal"},{"key":"1948_CR128","unstructured":"Pahwa R, Goyal A, Jialal I. Chronic Inflammation. In: StatPearls. Treasure Island (FL): StatPearls Publishing LLC; 2025. StatPearls Publishing Copyright \u00a9 2025."},{"issue":"1","key":"1948_CR129","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","volume":"6","author":"H Zhao","year":"2021","unstructured":"Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y, Li Y. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther. 2021;6(1):263.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1948_CR130","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s44276-025-00139-0","volume":"3","author":"AM Maagdenberg","year":"2025","unstructured":"Maagdenberg AM, Vledder A, Paijens ST, Plat A, Foijer F, Nijman HW, de Bruyn M. IL-6R expression is an independent prognostic factor in high-grade serous ovarian cancer. BJC Rep. 2025;3(1):49.","journal-title":"BJC Rep"},{"key":"1948_CR131","doi-asserted-by":"publisher","first-page":"1023177","DOI":"10.3389\/fonc.2022.1023177","volume":"12","author":"B Huang","year":"2022","unstructured":"Huang B, Lang X, Li X. The role of IL-6\/JAK2\/STAT3 signaling pathway in cancers. Front Oncol. 2022;12:1023177.","journal-title":"Front Oncol"},{"key":"1948_CR132","doi-asserted-by":"publisher","first-page":"866014","DOI":"10.3389\/fonc.2022.866014","volume":"12","author":"SG Manore","year":"2022","unstructured":"Manore SG, Doheny DL, Wong GL, Lo HW. IL-6\/JAK\/STAT3 signaling in breast cancer metastasis: biology and treatment. Front Oncol. 2022;12:866014.","journal-title":"Front Oncol"},{"key":"1948_CR133","doi-asserted-by":"publisher","first-page":"6685","DOI":"10.2147\/CMAR.S179189","volume":"10","author":"L Browning","year":"2018","unstructured":"Browning L, Patel MR, Horvath EB, Tawara K, Jorcyk CL. IL-6 and ovarian cancer: inflammatory cytokines in promotion of metastasis. Cancer Manag Res. 2018;10:6685\u201393.","journal-title":"Cancer Manag Res"},{"key":"1948_CR134","doi-asserted-by":"publisher","first-page":"656908","DOI":"10.3389\/fimmu.2021.656908","volume":"12","author":"D Laha","year":"2021","unstructured":"Laha D, Grant R, Mishra P, Nilubol N. The role of tumor necrosis factor in manipulating the immunological response of tumor microenvironment. Front Immunol. 2021;12:656908.","journal-title":"Front Immunol"},{"key":"1948_CR135","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.humpath.2016.03.006","volume":"54","author":"M Gupta","year":"2016","unstructured":"Gupta M, Babic A, Beck AH, Terry K. TNF-\u03b1 expression, risk factors, and inflammatory exposures in ovarian cancer: evidence for an inflammatory pathway of ovarian carcinogenesis? Hum Pathol. 2016;54:82\u201391.","journal-title":"Hum Pathol"},{"issue":"3","key":"1948_CR136","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.oraloncology.2012.09.012","volume":"49","author":"NL Costa","year":"2013","unstructured":"Costa NL, Valadares MC, Souza PP, Mendon\u00e7a EF, Oliveira JC, Silva TA, Batista AC. Tumor-associated macrophages and the profile of inflammatory cytokines in oral squamous cell carcinoma. Oral Oncol. 2013;49(3):216\u201323.","journal-title":"Oral Oncol"},{"issue":"1","key":"1948_CR137","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13287-015-0080-7","volume":"6","author":"C Katanov","year":"2015","unstructured":"Katanov C, Lerrer S, Liubomirski Y, Leider-Trejo L, Meshel T, Bar J, Feniger-Barish R, Kamer I, Soria-Artzi G, Kahani H, Banerjee D, Ben-Baruch A. Regulation of the inflammatory profile of stromal cells in human breast cancer: prominent roles for TNF-\u03b1 and the NF-\u03baB pathway. Stem Cell Res Ther. 2015;6(1):87.","journal-title":"Stem Cell Res Ther"},{"key":"1948_CR138","doi-asserted-by":"publisher","first-page":"563","DOI":"10.3389\/fimmu.2018.00563","volume":"9","author":"X Qu","year":"2018","unstructured":"Qu X, Tang Y, Hua S. Immunological approaches towards cancer and inflammation: A cross talk. Front Immunol. 2018;9:563.","journal-title":"Front Immunol"},{"key":"1948_CR139","doi-asserted-by":"publisher","first-page":"36107","DOI":"10.1038\/srep36107","volume":"6","author":"B Guo","year":"2016","unstructured":"Guo B, Fu S, Zhang J, Liu B, Li Z. Targeting inflammasome\/IL-1 pathways for cancer immunotherapy. Sci Rep. 2016;6:36107.","journal-title":"Sci Rep"},{"issue":"4","key":"1948_CR140","doi-asserted-by":"publisher","first-page":"48","DOI":"10.21037\/cco-23-135","volume":"13","author":"G Levin","year":"2024","unstructured":"Levin G, Gotlieb WH. Interleukine-10 in ovarian cancer. Chin Clin Oncol. 2024;13(4):48.","journal-title":"Chin Clin Oncol"},{"key":"1948_CR141","doi-asserted-by":"crossref","unstructured":"Liu W, Wang L, Zhang J, Cheng K, Zheng W, Ma Z, Chemokine CC. 2 Promotes Ovarian Cancer Progression through the MEK\/ERK\/MAP3K19 Signaling Pathway. Int J Mol Sci. 2023;24(13).","DOI":"10.3390\/ijms241310652"},{"issue":"2","key":"1948_CR142","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1111\/jcmm.14848","volume":"24","author":"J Wen","year":"2020","unstructured":"Wen J, Zhao Z, Huang L, Wang L, Miao Y, Wu J. IL-8 promotes cell migration through regulating EMT by activating the Wnt\/\u03b2-catenin pathway in ovarian cancer. J Cell Mol Med. 2020;24(2):1588\u201398.","journal-title":"J Cell Mol Med"},{"issue":"5\u20136","key":"1948_CR143","first-page":"247","volume":"22","author":"Q Guo","year":"2014","unstructured":"Guo Q, Gao BL, Zhang XJ, Liu GC, Xu F, Fan QY, Zhang SJ, Yang B, Wu XH. CXCL12-CXCR4 axis promotes Proliferation, Migration, Invasion, and metastasis of ovarian cancer. Oncol Res. 2014;22(5\u20136):247\u201358.","journal-title":"Oncol Res"},{"issue":"7","key":"1948_CR144","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.21873\/anticanres.16509","volume":"43","author":"H Lim","year":"2023","unstructured":"Lim H, Kim SI, Kim EN, Lee M, Lee C, Kim JW, Chung HH. Tissue expression and prognostic role of CXCL12 and CXCR4 in High-grade serous ovarian carcinoma. Anticancer Res. 2023;43(7):3331\u201340.","journal-title":"Anticancer Res"},{"issue":"2","key":"1948_CR145","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1002\/mco2.147","volume":"3","author":"H Li","year":"2020","unstructured":"Li H, Wu M, Zhao X. Role of chemokine systems in cancer and inflammatory diseases. MedComm (2020). 2022;3(2):e147.","journal-title":"MedComm (2020)"},{"issue":"7","key":"1948_CR146","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1080\/08820139.2017.1360342","volume":"46","author":"MMM Sanguinete","year":"2017","unstructured":"Sanguinete MMM, Oliveira PH, Martins-Filho A, Micheli DC, Tavares-Murta BM, Murta EFC, Nomelini RS. Serum IL-6 and IL-8 correlate with prognostic factors in ovarian cancer. Immunol Invest. 2017;46(7):677\u201388.","journal-title":"Immunol Invest"},{"issue":"3","key":"1948_CR147","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/mt.2010.247","volume":"19","author":"MA Salako","year":"2011","unstructured":"Salako MA, Kulbe H, Ingemarsdotter CK, Pirlo KJ, Williams SL, Lockley M, Balkwill FR, McNeish IA. Inhibition of the inflammatory cytokine TNF-\u03b1 increases adenovirus activity in ovarian cancer via modulation of cIAP1\/2 expression. Mol Ther. 2011;19(3):490\u20139.","journal-title":"Mol Ther"},{"issue":"6","key":"1948_CR148","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1080\/1354750X.2020.1783574","volume":"25","author":"DC Micheli","year":"2020","unstructured":"Micheli DC, Jammal MP, Martins-Filho A, C\u00f4rtes J, Souza CN, Nomelini RS, Murta EFC, Tavares-Murta BM. Serum cytokines and CXCR2: potential tumour markers in ovarian neoplasms. Biomarkers. 2020;25(6):474\u201382.","journal-title":"Biomarkers"},{"issue":"4","key":"1948_CR149","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ccr.2009.02.015","volume":"15","author":"H Lee","year":"2009","unstructured":"Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z, Forman S, Jove R, Pardoll DM, Yu H. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell. 2009;15(4):283\u201393.","journal-title":"Cancer Cell"},{"issue":"3","key":"1948_CR150","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/intimm\/dxaa078","volume":"33","author":"T Hirano","year":"2021","unstructured":"Hirano T. IL-6 in inflammation, autoimmunity and cancer. Int Immunol. 2021;33(3):127\u201348.","journal-title":"Int Immunol"},{"key":"1948_CR151","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.3389\/fonc.2019.01370","volume":"9","author":"S Quintero-Fabi\u00e1n","year":"2019","unstructured":"Quintero-Fabi\u00e1n S, Arreola R, Becerril-Villanueva E, Torres-Romero JC, Arana-Arg\u00e1ez V, Lara-Riegos J, Ram\u00edrez-Camacho MA, Alvarez-S\u00e1nchez ME. Role of matrix metalloproteinases in angiogenesis and cancer. Front Oncol. 2019;9:1370.","journal-title":"Front Oncol"},{"issue":"11","key":"1948_CR152","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423\u201337.","journal-title":"Nat Med"},{"issue":"4","key":"1948_CR153","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/resp.12729","volume":"21","author":"RL Harper","year":"2016","unstructured":"Harper RL, Reynolds AM, Bonder CS, Reynolds PN. BMPR2 gene therapy for PAH acts via Smad and non-Smad signalling. Respirology. 2016;21(4):727\u201333.","journal-title":"Respirology"},{"issue":"5987","key":"1948_CR154","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1126\/science.1188995","volume":"329","author":"T Ikawa","year":"2010","unstructured":"Ikawa T, Hirose S, Masuda K, Kakugawa K, Satoh R, Shibano-Satoh A, Kominami R, Katsura Y, Kawamoto H. An essential developmental checkpoint for production of the T cell lineage. Science. 2010;329(5987):93\u20136.","journal-title":"Science"},{"issue":"24","key":"1948_CR155","doi-asserted-by":"publisher","first-page":"18134","DOI":"10.1074\/jbc.C110.106377","volume":"285","author":"Y Yamashita","year":"2010","unstructured":"Yamashita Y, Yamashita M. Identification of a novel selenium-containing compound, selenoneine, as the predominant chemical form of organic selenium in the blood of Bluefin tuna. J Biol Chem. 2010;285(24):18134\u20138.","journal-title":"J Biol Chem"},{"issue":"7","key":"1948_CR156","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s11745-014-3915-6","volume":"49","author":"M Medina","year":"2014","unstructured":"Medina M, Alberto MR, Sierra L, Van Nieuwenhove C, Saad S, Isla MI, Jerez S. Hypercholesterolemia increases plasma saturated and n-6 fatty acids altering prostaglandin homeostasis and promotes endothelial dysfunction in rabbits. Lipids. 2014;49(7):685\u201393.","journal-title":"Lipids"},{"issue":"9","key":"1948_CR157","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1016\/j.neuropsychologia.2011.06.004","volume":"49","author":"JC Goll","year":"2011","unstructured":"Goll JC, Kim LG, Hailstone JC, Lehmann M, Buckley A, Crutch SJ, Warren JD. Auditory object cognition in dementia. Neuropsychologia. 2011;49(9):2755\u201365.","journal-title":"Neuropsychologia"},{"issue":"11","key":"1948_CR158","first-page":"11288","volume":"10","author":"F Hua","year":"2017","unstructured":"Hua F, Tian Y. CCL4 promotes the cell proliferation, invasion and migration of endometrial carcinoma by targeting the VEGF-A signal pathway. Int J Clin Exp Pathol. 2017;10(11):11288\u201399.","journal-title":"Int J Clin Exp Pathol"},{"issue":"5","key":"1948_CR159","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/mc.23289","volume":"60","author":"S Kim","year":"2021","unstructured":"Kim S, Han Y, Kim SI, Lee J, Jo H, Wang W, Cho U, Park WY, Rando TA, Dhanasekaran DN, Song YS. Computational modeling of malignant Ascites reveals CCL5-SDC4 interaction in the immune microenvironment of ovarian cancer. Mol Carcinog. 2021;60(5):297\u2013312.","journal-title":"Mol Carcinog"},{"issue":"5","key":"1948_CR160","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s12032-023-01987-x","volume":"40","author":"AA El-Arabey","year":"2023","unstructured":"El-Arabey AA, Alkhalil SS, Al-Shouli ST, Awadalla ME, Alhamdi HW, Almanaa TN, Mohamed S, Abdalla M. Revisiting macrophages in ovarian cancer microenvironment: development, function and interaction. Med Oncol. 2023;40(5):142.","journal-title":"Med Oncol"},{"key":"1948_CR161","doi-asserted-by":"publisher","first-page":"8859554","DOI":"10.1155\/2021\/8859554","volume":"2021","author":"Y Jin","year":"2021","unstructured":"Jin Y, Lin Q, Fei H, Xue L, Li L, Xi Q, Jiang H. Bioinformatics analysis of potential therapeutic targets and prognostic biomarkers amid CXC chemokines in ovarian carcinoma microenvironment. J Oncol. 2021;2021:8859554.","journal-title":"J Oncol"},{"issue":"5","key":"1948_CR162","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3390\/pathogens9050403","volume":"9","author":"CD James","year":"2020","unstructured":"James CD, Morgan IM, Bristol ML. The relationship between estrogen-related signaling and human papillomavirus positive cancers. Pathogens. 2020;9(5):403.","journal-title":"Pathogens"},{"issue":"1","key":"1948_CR163","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12885-022-09247-3","volume":"22","author":"S Fischer","year":"2022","unstructured":"Fischer S, Kuebler U, Abbruzzese E, Breymann C, Mernone L, Ehlert U. Endogenous oestradiol and progesterone as predictors of oncogenic human papillomavirus (HPV) persistence. BMC Cancer. 2022;22(1):145.","journal-title":"BMC Cancer"},{"issue":"1","key":"1948_CR164","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s12672-024-01675-w","volume":"15","author":"R Zhao","year":"2024","unstructured":"Zhao R, Lian W, Xu Q. Sex hormones and immune regulation in ovarian cancer. Discover Oncol. 2024;15(1):849.","journal-title":"Discover Oncol"},{"issue":"6","key":"1948_CR165","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1210\/endrev\/bnad018","volume":"44","author":"LJ Mauro","year":"2023","unstructured":"Mauro LJ, Spartz A, Austin JR, Lange CA. Reevaluating the role of progesterone in ovarian cancer: is progesterone always protective? Endocr Rev. 2023;44(6):1029\u201346.","journal-title":"Endocr Rev"},{"issue":"11","key":"1948_CR166","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1210\/me.2006-0112","volume":"20","author":"DB Hardy","year":"2006","unstructured":"Hardy DB, Janowski BA, Corey DR, Mendelson CR. Progesterone receptor plays a major antiinflammatory role in human myometrial cells by antagonism of nuclear Factor-\u03baB activation of cyclooxygenase 2 expression. Mol Endocrinol. 2006;20(11):2724\u201333.","journal-title":"Mol Endocrinol"},{"key":"1948_CR167","doi-asserted-by":"publisher","first-page":"1500251","DOI":"10.3389\/fphar.2025.1500251","volume":"16","author":"J Wang","year":"2025","unstructured":"Wang J, Zhu W, Li X, Wu Y, Ma W, Wang Y, Zhao W, Wei F, Wang W. Transcriptome analysis of ovarian cancer uncovers association between tumor-related inflammation\/immunity and patient outcome. Front Pharmacol. 2025;16:1500251.","journal-title":"Front Pharmacol"},{"issue":"5","key":"1948_CR168","doi-asserted-by":"publisher","first-page":"406","DOI":"10.37349\/ei.2021.00027","volume":"1","author":"J Szekeres-Bartho","year":"2021","unstructured":"Szekeres-Bartho J. Progesterone induced blocking factor in health and disease. Explor Immunol. 2021;1(5):406\u201317.","journal-title":"Explor Immunol"},{"issue":"1","key":"1948_CR169","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s12935-019-0935-6","volume":"19","author":"IG Ram\u00edrez-L\u00f3pez","year":"2019","unstructured":"Ram\u00edrez-L\u00f3pez IG, Ram\u00edrez de Arellano A, Jave-Su\u00e1rez LF, Hern\u00e1ndez-Silva CD, Garc\u00eda-Chagollan M, Hern\u00e1ndez-Bello J, Lopez-Pulido EI, Macias-Barragan J, Montoya-Buelna M, Mu\u00f1oz-Valle JF, Pereira-Su\u00e1rez AL. Interaction between 17\u03b2-estradiol, prolactin and human papillomavirus induce E6\/E7 transcript and modulate the expression and localization of hormonal receptors. Cancer Cell Int. 2019;19(1):227","journal-title":"Cancer Cell Int"},{"issue":"7","key":"1948_CR170","doi-asserted-by":"publisher","first-page":"937","DOI":"10.3390\/v17070937","volume":"17","author":"K Schichl","year":"2025","unstructured":"Schichl K, Doorbar J. Regulation and deregulation of viral gene expression during High-Risk HPV infection. Viruses. 2025;17(7):937.","journal-title":"Viruses"},{"issue":"1","key":"1948_CR171","first-page":"153","volume":"26","author":"A Kwasniewska","year":"2011","unstructured":"Kwasniewska A, Postawski K, Gozdzicka-Jozefiak A, Kwasniewski W, Grywalska E, Zdunek M, Korobowicz E. Estrogen and progesterone receptor expression in HPV-positive and HPV-negative cervical carcinomas. Oncol Rep. 2011;26(1):153\u201360.","journal-title":"Oncol Rep"},{"key":"1948_CR173","doi-asserted-by":"publisher","first-page":"672853","DOI":"10.3389\/fimmu.2021.672853","volume":"12","author":"L Quatrini","year":"2021","unstructured":"Quatrini L, Ricci B, Ciancaglini C, Tumino N, Moretta L. Regulation of the immune system development by glucocorticoids and sex hormones. Front Immunol. 2021;12:672853.","journal-title":"Front Immunol"},{"issue":"9","key":"1948_CR174","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3390\/biom12091299","volume":"12","author":"TA Fedotcheva","year":"2022","unstructured":"Fedotcheva TA, Fedotcheva NI, Shimanovsky NL. Progesterone as an Anti-Inflammatory drug and immunomodulator: new aspects in hormonal regulation of the inflammation. Biomolecules. 2022;12(9):1299.","journal-title":"Biomolecules"},{"issue":"11","key":"1948_CR175","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.3390\/cells11111785","volume":"11","author":"P Thomas","year":"2022","unstructured":"Thomas P. Membrane progesterone receptors (mPRs, PAQRs): review of structural and signaling characteristics. Cells. 2022;11(11):1785.","journal-title":"Cells"},{"issue":"4","key":"1948_CR176","doi-asserted-by":"publisher","first-page":"e0266144","DOI":"10.1371\/journal.pone.0266144","volume":"17","author":"L Cui","year":"2022","unstructured":"Cui L, Shao X, Sun W, Zheng F, Dong J, Li J, Wang H, Li J. Anti-inflammatory effects of progesterone through NF-\u03baB and MAPK pathway in lipopolysaccharide-or Escherichia coli-stimulated bovine endometrial stromal cells. PLoS ONE. 2022;17(4):e0266144.","journal-title":"PLoS ONE"},{"key":"1948_CR177","doi-asserted-by":"crossref","unstructured":"Choi J, Jo M, Lee E, Kim SE, Lee D-Y, Choi D. Inhibition of the NLRP3 inflammasome by progesterone is attenuated by abnormal autophagy induction in endometriotic cyst stromal cells: implications for endometriosis. Mol Hum Reprod. 2022;28(4).","DOI":"10.1093\/molehr\/gaac007"},{"key":"1948_CR178","doi-asserted-by":"crossref","unstructured":"Islam MS, Afrin S, Jones SI, Segars J. Selective progesterone receptor modulators\u2014mechanisms therapeutic utility. Endocr Reviews. 2020;41(5).","DOI":"10.1210\/endrev\/bnaa012"},{"issue":"16","key":"1948_CR179","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1056\/NEJMra2022774","volume":"383","author":"N Mizushima","year":"2020","unstructured":"Mizushima N, Levine B. Autophagy in human diseases. N Engl J Med. 2020;383(16):1564\u201376.","journal-title":"N Engl J Med"},{"issue":"4","key":"1948_CR180","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1093\/biolre\/ioz234","volume":"102","author":"AK Oestreich","year":"2020","unstructured":"Oestreich AK, Chadchan SB, Medvedeva A, Lydon JP, Jungheim ES, Moley KH, Kommagani R. The autophagy protein, FIP200 (RB1CC1) mediates progesterone responses governing uterine receptivity and decidualization\u2020. Biol Reprod. 2020;102(4):843\u201351.","journal-title":"Biol Reprod"},{"issue":"3","key":"1948_CR181","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3892\/ijo.2017.3873","volume":"50","author":"X Zhu","year":"2017","unstructured":"Zhu X, Ji M, Han Y, Guo Y, Zhu W, Gao F, Yang X, Zhang C. PGRMC1-dependent autophagy by Hyperoside induces apoptosis and sensitizes ovarian cancer cells to cisplatin treatment. Int J Oncol. 2017;50(3):835\u201346.","journal-title":"Int J Oncol"},{"issue":"5","key":"1948_CR182","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41419-023-05864-3","volume":"14","author":"Y Esmaeilian","year":"2023","unstructured":"Esmaeilian Y, Hela F, Bildik G, \u0130ltumur E, Yusufoglu S, Yildiz CS, Yakin K, Kordan Y, Oktem O. Autophagy regulates sex steroid hormone synthesis through lysosomal degradation of lipid droplets in human ovary and testis. Cell Death Dis. 2023;14(5):342.","journal-title":"Cell Death Dis"},{"key":"1948_CR183","doi-asserted-by":"publisher","first-page":"1384047","DOI":"10.3389\/fcell.2024.1384047","volume":"12","author":"A Afzal","year":"2024","unstructured":"Afzal A, Zhang Y, Afzal H, Saddozai UAK, Zhang L, Ji XY, Khawar MB. Functional role of autophagy in testicular and ovarian steroidogenesis. Front Cell Dev Biol. 2024;12:1384047.","journal-title":"Front Cell Dev Biol"},{"issue":"9","key":"1948_CR184","doi-asserted-by":"publisher","first-page":"4404","DOI":"10.1002\/cam4.2351","volume":"8","author":"C Tingting","year":"2019","unstructured":"Tingting C, Shizhou Y, Songfa Z, Junfen X, Weiguo L, Xiaodong C, Xing X. Human papillomavirus 16E6\/E7 activates autophagy via Atg9B and LAMP1 in cervical cancer cells. Cancer Med. 2019;8(9):4404\u201316.","journal-title":"Cancer Med"},{"key":"1948_CR185","doi-asserted-by":"crossref","unstructured":"Lai W, Liu S, Wang T, Gong M, Liu Q, Ling L, Chen J. PGRMC1 promotes the development of cervical intraepithelial neoplasia in HPV-positive patients. Biomedicines. 2025;13(10).","DOI":"10.3390\/biomedicines13102454"},{"key":"1948_CR186","doi-asserted-by":"publisher","first-page":"1039260","DOI":"10.3389\/fimmu.2022.1039260","volume":"13","author":"C Lu","year":"2022","unstructured":"Lu C, Liu Y, Ali NM, Zhang B, Cui X. The role of innate immune cells in the tumor microenvironment and research progress in anti-tumor therapy. Front Immunol. 2022;13:1039260.","journal-title":"Front Immunol"},{"key":"1948_CR187","doi-asserted-by":"publisher","first-page":"101759","DOI":"10.1016\/j.redox.2020.101759","volume":"37","author":"L Sun","year":"2020","unstructured":"Sun L, Wang X, Saredy J, Yuan Z, Yang X, Wang H. Innate-adaptive immunity interplay and redox regulation in immune response. Redox Biol. 2020;37:101759.","journal-title":"Redox Biol"},{"issue":"1","key":"1948_CR188","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41392-025-02264-1","volume":"10","author":"R Chen","year":"2025","unstructured":"Chen R, Zou J, Chen J, Zhong X, Kang R, Tang D. Pattern recognition receptors: function, regulation and therapeutic potential. Signal Transduct Target Therapy. 2025;10(1):216.","journal-title":"Signal Transduct Target Therapy"},{"issue":"5","key":"1948_CR189","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.jaci.2010.01.058","volume":"125","author":"Y Kumagai","year":"2010","unstructured":"Kumagai Y, Akira S. Identification and functions of pattern-recognition receptors. J Allergy Clin Immunol. 2010;125(5):985\u201392.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"1948_CR190","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.cell.2010.01.022","volume":"140","author":"O Takeuchi","year":"2010","unstructured":"Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140(6):805\u201320.","journal-title":"Cell"},{"issue":"1","key":"1948_CR191","doi-asserted-by":"publisher","first-page":"e27257","DOI":"10.4161\/onci.27257","volume":"3","author":"U Hasan","year":"2014","unstructured":"Hasan U. Human papillomavirus (HPV) deregulation of Toll-like receptor 9. Oncoimmunology. 2014;3(1):e27257.","journal-title":"Oncoimmunology"},{"issue":"1","key":"1948_CR192","first-page":"1","volume":"2","author":"X Yang","year":"2017","unstructured":"Yang X, Cheng Y, Li C. The role of TLRs in cervical cancer with HPV infection: a review. Signal Transduct Target Therapy. 2017;2(1):1\u201310.","journal-title":"Signal Transduct Target Therapy"},{"key":"1948_CR193","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3389\/fimmu.2020.00211","volume":"11","author":"C Zhao","year":"2020","unstructured":"Zhao C, Zhao W. NLRP3 inflammasome\u2014a key player in antiviral responses. Front Immunol. 2020;11:211.","journal-title":"Front Immunol"},{"issue":"1","key":"1948_CR194","doi-asserted-by":"publisher","first-page":"e28220","DOI":"10.1002\/jmv.28220","volume":"95","author":"S Shen","year":"2023","unstructured":"Shen S, Rui Y, Wang Y, Su J, Yu XF. SARS-CoV\u20102, HIV, and HPV: convergent evolution of selective regulation of cGAS\u2013STING signaling. J Med Virol. 2023;95(1):e28220.","journal-title":"J Med Virol"},{"issue":"5","key":"1948_CR195","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3390\/pathogens14050464","volume":"14","author":"S Roy-Biswas","year":"2025","unstructured":"Roy-Biswas S, Hibma M. The epithelial immune response to human papillomavirus infection. Pathogens. 2025;14(5):464.","journal-title":"Pathogens"},{"key":"1948_CR196","doi-asserted-by":"crossref","unstructured":"Oh S, Choi YK, Lee S. Pattern recognition receptors and inflammasome: now and beyond. Mol Cells. 2025;100239.","DOI":"10.1016\/j.mocell.2025.100239"},{"issue":"8","key":"1948_CR197","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s12272-012-0802-7","volume":"35","author":"S Basith","year":"2012","unstructured":"Basith S, Manavalan B, Yoo TH, Kim SG, Choi S. Roles of toll-like receptors in cancer: a double-edged sword for defense and offense. Arch Pharm Res. 2012;35(8):1297\u2013316.","journal-title":"Arch Pharm Res"},{"issue":"5","key":"1948_CR198","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1099\/jgv.0.001057","volume":"99","author":"LB Oliveira","year":"2018","unstructured":"Oliveira LB, Haga IR, Villa LL. Human papillomavirus (HPV) 16 E6 oncoprotein targets the Toll-like receptor pathway. J Gen Virol. 2018;99(5):667\u201375.","journal-title":"J Gen Virol"},{"issue":"1","key":"1948_CR199","first-page":"2912671","volume":"2018","author":"MR Barros Jr","year":"2018","unstructured":"Barros MR Jr, de Oliveira THA, de Melo CML, Venuti A, de Freitas AC. Viral modulation of TLRs and cytokines and the related immunotherapies for HPV-associated cancers. J Immunol Res. 2018;2018(1):2912671.","journal-title":"J Immunol Res"},{"issue":"3","key":"1948_CR200","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.3892\/ol.2015.2884","volume":"9","author":"JV Fernandes","year":"2015","unstructured":"Fernandes JV, D.E.M.F. TA, D.E.A. JC RN, Cobucci DEC, MG VS, Andrade, JM DEA. Link between chronic inflammation and human papillomavirus-induced carcinogenesis (Review). Oncol Lett. 2015;9(3):1015\u201326.","journal-title":"Oncol Lett"},{"key":"1948_CR201","doi-asserted-by":"publisher","first-page":"590941","DOI":"10.3389\/fonc.2020.590941","volume":"10","author":"Z Ge","year":"2020","unstructured":"Ge Z, Ding S. The crosstalk between tumor-Associated macrophages (TAMs) and tumor cells and the corresponding targeted therapy. Front Oncol. 2020;10:590941.","journal-title":"Front Oncol"},{"issue":"1","key":"1948_CR202","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12967-024-06036-3","volume":"23","author":"K Chen","year":"2025","unstructured":"Chen K, Li X, Dong S, Guo Y, Luo Z, Zhuang S-M, Liu J, Liu T, Liao J, Wen W. Modulating tumor-associated macrophages through CSF1R inhibition: a potential therapeutic strategy for HNSCC. J Translational Med. 2025;23(1):27.","journal-title":"J Translational Med"},{"issue":"1","key":"1948_CR203","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13046-025-03377-9","volume":"44","author":"Y Yang","year":"2025","unstructured":"Yang Y, Li S, To KKW, Zhu S, Wang F, Fu L. Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy. J Experimental Clin Cancer Res. 2025;44(1):145.","journal-title":"J Experimental Clin Cancer Res"},{"issue":"1","key":"1948_CR204","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12935-022-02527-9","volume":"22","author":"NNV Radharani","year":"2022","unstructured":"Radharani NNV, Yadav AS, Nimma R, Kumar TVS, Bulbule A, Chanukuppa V, Kumar D, Patnaik S, Rapole S, Kundu GC. Tumor-associated macrophage derived IL-6 enriches cancer stem cell population and promotes breast tumor progression via Stat-3 pathway. Cancer Cell Int. 2022;22(1):122.","journal-title":"Cancer Cell Int"},{"issue":"6","key":"1948_CR205","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.3390\/cancers17061012","volume":"17","author":"AG El-Shemi","year":"2025","unstructured":"El-Shemi AG, Alqurashi A, Abdulrahman JA, Alzahrani HD, Almwalad KS, Felfilan HH, Alomiri WS, Aloufi JA, Madkhali GH, Maqliyah SA, Alshahrani JB, Kamal HT, Daghistani SH, Refaat B, Minshawi F. IL-10-Directed cancer immunotherapy: preclinical Advances, clinical Insights, and future perspectives. Cancers. 2025;17(6):1012.","journal-title":"Cancers"},{"issue":"5","key":"1948_CR206","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.3390\/microorganisms13051000","volume":"13","author":"LA Pavelescu","year":"2025","unstructured":"Pavelescu LA, Mititelu-Zafiu NL, Mindru DE, Vladareanu R, Curici A. Molecular insights into HPV-Driven cervical cancer: Oncoproteins, immune Evasion, and epigenetic modifications. Microorganisms. 2025;13(5):1000.","journal-title":"Microorganisms"},{"issue":"4","key":"1948_CR207","doi-asserted-by":"publisher","first-page":"BSR20181709","DOI":"10.1042\/BSR20181709","volume":"39","author":"FJ Velloso","year":"2019","unstructured":"Velloso FJ, Trombetta-Lima M, Anschau V, Sogayar MC, Correa RG. NOD-like receptors: major players (and targets) in the interface between innate immunity and cancer. Biosci Rep. 2019;39(4):BSR20181709.","journal-title":"Biosci Rep"},{"issue":"1","key":"1948_CR208","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13027-020-0272-3","volume":"15","author":"X Liu","year":"2020","unstructured":"Liu X, Ma H, Fei L, Jiang M, Xia M, Bai L, Pi X, Chen S, Yu L. HPV-mediated down-regulation of NOD1 inhibits apoptosis in cervical cancer. Infect Agents Cancer. 2020;15(1):6.","journal-title":"Infect Agents Cancer"},{"issue":"1","key":"1948_CR209","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s00018-025-05575-2","volume":"82","author":"D Ren","year":"2025","unstructured":"Ren D, Ye X, Chen R, Jia X, He X, Tao J, Jin T, Wu S, Zhang H. Activation and evasion of inflammasomes during viral and microbial infection. Cell Mol Life Sci. 2025;82(1):56.","journal-title":"Cell Mol Life Sci"},{"key":"1948_CR210","doi-asserted-by":"publisher","first-page":"1549766","DOI":"10.3389\/fimmu.2025.1549766","volume":"16","author":"J-X Li","year":"2025","unstructured":"Li J-X, Zhang J, Li C-H, Li Y-F, Chen H-M, Li T, Zhang Q, Kong B-H, Wang P-H. Human papillomavirus E1 proteins inhibit RIG-I\/MDA5-MAVS, TLR3-TRIF, cGAS-STING, and JAK-STAT signaling pathways to evade innate antiviral immunity. Front Immunol. 2025;16:1549766.","journal-title":"Front Immunol"},{"issue":"6","key":"1948_CR211","doi-asserted-by":"publisher","first-page":"01737","DOI":"10.1128\/jvi","volume":"92","author":"C Chiang","year":"2018","unstructured":"Chiang C, Pauli E-K, Biryukov J, Feister KF, Meng M, White EA, M\u00fcnger K, Howley PM, Meyers C, Gack MU. The human papillomavirus E6 oncoprotein targets USP15 and TRIM25 to suppress RIG-I-mediated innate immune signaling. J Virol. 2018;92(6):01737\u201317. https:\/\/doi.org\/10.1128\/jvi.","journal-title":"J Virol"},{"key":"1948_CR212","doi-asserted-by":"publisher","unstructured":"Nakaya Y, Lilue J, Stavrou S, Moran EA, Ross SR AIM2-like receptors positively and negatively regulate the interferon response induced by cytosolic DNA. MBio. 2017;8(4). https:\/\/doi.org\/10.1128\/mbio.00944-17.","DOI":"10.1128\/mbio.00944-17"},{"issue":"15","key":"1948_CR213","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.7150\/ijbs.50074","volume":"16","author":"Y Song","year":"2020","unstructured":"Song Y, Wu X, Xu Y, Zhu J, Li J, Zou Z, Chen L, Zhang B, Hua C, Rui H. HPV E7 inhibits cell pyroptosis by promoting TRIM21-mediated degradation and ubiquitination of the IFI16 inflammasome. Int J Biol Sci. 2020;16(15):2924.","journal-title":"Int J Biol Sci"},{"issue":"8","key":"1948_CR214","doi-asserted-by":"publisher","first-page":"e1003536","DOI":"10.1371\/journal.ppat.1003536","volume":"9","author":"M Niebler","year":"2013","unstructured":"Niebler M, Qian X, H\u00f6fler D, Kogosov V, Kaewprag J, Kaufmann AM, Ly R, B\u00f6hmer G, Zawatzky R, R\u00f6sl F, Rincon-Orozco B. Post-translational control of IL-1\u03b2 via the human papillomavirus type 16 E6 oncoprotein: a novel mechanism of innate immune escape mediated by the E3-ubiquitin ligase E6-AP and p53. PLoS Pathog. 2013;9(8):e1003536.","journal-title":"PLoS Pathog"},{"issue":"1","key":"1948_CR215","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.25083\/rbl\/26.1\/2255.2259","volume":"26","author":"R Stroe","year":"2021","unstructured":"Stroe R, Mambet C, Curici A, Ivan F, Alexa L, Morjan C, Hodis N, Matei L, Dragu LD, Lazar V. Differential expression of NLRP3 inflammasome genes in HPV infected cervical cells. Romanian Biotechnol Lett. 2021;26(1):2255\u201361.","journal-title":"Romanian Biotechnol Lett"},{"key":"1948_CR216","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3389\/fimmu.2017.00271","volume":"8","author":"C Lin","year":"2017","unstructured":"Lin C, Zhang J. Inflammasomes in inflammation-induced cancer. Front Immunol. 2017;8:271.","journal-title":"Front Immunol"},{"issue":"1","key":"1948_CR217","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s13238-013-0001-4","volume":"5","author":"R Kolb","year":"2014","unstructured":"Kolb R, Liu G-H, Janowski AM, Sutterwala FS, Zhang W. Inflammasomes in cancer: a double-edged sword. Protein Cell. 2014;5(1):12\u201320.","journal-title":"Protein Cell"},{"issue":"6","key":"1948_CR218","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.cell.2010.01.040","volume":"140","author":"K Schroder","year":"2010","unstructured":"Schroder K, Tschopp J. The Inflammasomes Cell. 2010;140(6):821\u201332.","journal-title":"The Inflammasomes Cell"},{"key":"1948_CR219","doi-asserted-by":"publisher","first-page":"1451305","DOI":"10.3389\/fimmu.2024.1451305","volume":"15","author":"C Shao","year":"2024","unstructured":"Shao C, Chen J, Qiang B, Ye J, Yan F, Zhu Y. The role of cGAS-STING signaling in the development and therapy of head and neck squamous cell carcinoma. Front Immunol. 2024;15:1451305.","journal-title":"Front Immunol"},{"issue":"2","key":"1948_CR220","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00005-017-0481-7","volume":"66","author":"O Sokolowska","year":"2018","unstructured":"Sokolowska O, Nowis D. STING signaling in cancer cells: important or not? Arch Immunol Ther Exp. 2018;66(2):125\u201332.","journal-title":"Arch Immunol Ther Exp"},{"issue":"214","key":"1948_CR221","doi-asserted-by":"publisher","first-page":"ra20","DOI":"10.1126\/scisignal.2002521","volume":"5","author":"Y Tanaka","year":"2012","unstructured":"Tanaka Y, Chen ZJ. STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway. Sci Signal. 2012;5(214):ra20\u201320.","journal-title":"Sci Signal"},{"issue":"1","key":"1948_CR222","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/imr.12903","volume":"297","author":"P Kumari","year":"2020","unstructured":"Kumari P, Russo AJ, Shivcharan S, Rathinam VA. AIM2 in health and disease: inflammasome and beyond. Immunol Rev. 2020;297(1):83\u201395.","journal-title":"Immunol Rev"},{"issue":"1","key":"1948_CR223","doi-asserted-by":"publisher","first-page":"157","DOI":"10.7150\/jca.101473","volume":"16","author":"L Sui","year":"2025","unstructured":"Sui L, Xi Y, Zheng S, Xiao Q, Liu Z. The role of AIM2 in cancer development: inflammasomes and beyond. J Cancer. 2025;16(1):157.","journal-title":"J Cancer"},{"issue":"8","key":"1948_CR224","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00403-013-1375-0","volume":"305","author":"M Reinholz","year":"2013","unstructured":"Reinholz M, Kawakami Y, Salzer S, Kreuter A, Dombrowski Y, Koglin S, Kresse S, Ruzicka T, Schauber J. HPV16 activates the AIM2 inflammasome in keratinocytes. Arch Dermatol Res. 2013;305(8):723\u201332.","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"1948_CR225","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3390\/cancers12030646","volume":"12","author":"AR Ferreira","year":"2020","unstructured":"Ferreira AR, Ramalho AC, Marques M, Ribeiro D. The interplay between antiviral signalling and carcinogenesis in human papillomavirus infections. Cancers. 2020;12(3):646.","journal-title":"Cancers"},{"issue":"4","key":"1948_CR226","doi-asserted-by":"publisher","first-page":"716","DOI":"10.3390\/futurepharmacol4040038","volume":"4","author":"A Cruz-Gregorio","year":"2024","unstructured":"Cruz-Gregorio A, Aranda-Rivera AK, Pedraza-Chaverri J. HPV proteins as therapeutic targets for phytopharmaceuticals related to redox state in HPV-Related cancers. Future Pharmacol. 2024;4(4):716\u201330.","journal-title":"Future Pharmacol"},{"issue":"1","key":"1948_CR227","first-page":"5315816","volume":"2018","author":"SR Georgescu","year":"2018","unstructured":"Georgescu SR, Mitran CI, Mitran MI, Caruntu C, Sarbu MI, Matei C, Nicolae I, Tocut SM, Popa MI, Tampa M. New insights in the pathogenesis of HPV infection and the associated carcinogenic processes: the role of chronic inflammation and oxidative stress. J Immunol Res. 2018;2018(1):5315816.","journal-title":"J Immunol Res"},{"issue":"1","key":"1948_CR228","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40001-025-02605-4","volume":"30","author":"OS Ardekani","year":"2025","unstructured":"Ardekani OS, Letafati A, Dehkordi SE, Farahani AV, Bahari M, Mahdavi B, Ariamand N, Taghvaei M, Kohkalani M, Pirkooh AA. From infection to infertility: a review of the role of human papillomavirus-induced oxidative stress on reproductive health and infertility. Eur J Med Res. 2025;30(1):1\u201330.","journal-title":"Eur J Med Res"},{"issue":"3","key":"1948_CR229","first-page":"254","volume":"2","author":"B Tudek","year":"2010","unstructured":"Tudek B, Winczura A, Janik J, Siomek A, Foksinski M, Oli\u0144ski R. Involvement of oxidatively damaged DNA and repair in cancer development and aging. Am J Translational Res. 2010;2(3):254.","journal-title":"Am J Translational Res"},{"issue":"1","key":"1948_CR230","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13027-024-00581-8","volume":"19","author":"A Letafati","year":"2024","unstructured":"Letafati A, Taghiabadi Z, Zafarian N, Tajdini R, Mondeali M, Aboofazeli A, Chichiarelli S, Saso L, Jazayeri SM. Emerging paradigms: unmasking the role of oxidative stress in HPV-induced carcinogenesis. Infect Agents Cancer. 2024;19(1):30.","journal-title":"Infect Agents Cancer"},{"issue":"1","key":"1948_CR231","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1186\/s12885-020-07428-6","volume":"20","author":"M Rezaei","year":"2020","unstructured":"Rezaei M, Mostafaei S, Aghaei A, Hosseini N, Darabi H, Nouri M, Etemadi A, Neill AO, Nahand JS, Mirzaei H. The association between HPV gene expression, inflammatory agents and cellular genes involved in EMT in lung cancer tissue. BMC Cancer. 2020;20(1):916.","journal-title":"BMC Cancer"},{"issue":"12","key":"1948_CR232","doi-asserted-by":"publisher","first-page":"6751","DOI":"10.1128\/JVI.03355-13","volume":"88","author":"VM Williams","year":"2014","unstructured":"Williams VM, Filippova M, Filippov V, Payne KJ, Duerksen-Hughes P. Human papillomavirus type 16 E6* induces oxidative stress and DNA damage. J Virol. 2014;88(12):6751\u201361.","journal-title":"J Virol"},{"issue":"2","key":"1948_CR233","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1136\/ijgc-2020-001587","volume":"31","author":"DP Preci","year":"2021","unstructured":"Preci DP, Almeida A, Weiler AL, Franciosi MLM, Cardoso AM. Oxidative damage and antioxidants in cervical cancer. Int J Gynecol Cancer. 2021;31(2):265\u201371.","journal-title":"Int J Gynecol Cancer"},{"issue":"34","key":"1948_CR234","doi-asserted-by":"publisher","first-page":"23824","DOI":"10.18632\/oncotarget.25323","volume":"9","author":"GM Calaf","year":"2018","unstructured":"Calaf GM, Urzua U, Termini L, Aguayo F. Oxidative stress in female cancers. Oncotarget. 2018;9(34):23824.","journal-title":"Oncotarget"},{"issue":"3","key":"1948_CR235","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3390\/cells12030416","volume":"12","author":"I Ray","year":"2023","unstructured":"Ray I, Michael A, Meira LB, Ellis PE. The role of cytokines in epithelial\u2013mesenchymal transition in gynaecological cancers: a systematic review. Cells. 2023;12(3):416.","journal-title":"Cells"},{"issue":"24","key":"1948_CR236","doi-asserted-by":"publisher","first-page":"13543","DOI":"10.3390\/ijms222413543","volume":"22","author":"G Barillari","year":"2021","unstructured":"Barillari G, Bei R, Manzari V, Modesti A. Infection by high-risk human papillomaviruses, epithelial-to-mesenchymal transition and squamous pre-malignant or malignant lesions of the uterine cervix: a series of chained events? Int J Mol Sci. 2021;22(24):13543.","journal-title":"Int J Mol Sci"},{"key":"1948_CR237","doi-asserted-by":"publisher","first-page":"1520771","DOI":"10.3389\/fphar.2025.1520771","volume":"16","author":"S Chen","year":"2025","unstructured":"Chen S, Kong W, Shen X, Sinha N, Haag J, Deng B, Zhang H, John C, Sun W, Zhou C, Bae-Jump VL. Sulindac exhibits anti-proliferative and anti-invasive effects and enhances the sensitivity to paclitaxel in ovarian cancer. Front Pharmacol. 2025;16:1520771.","journal-title":"Front Pharmacol"},{"key":"1948_CR238","doi-asserted-by":"publisher","first-page":"895","DOI":"10.2147\/JIR.S503479","volume":"18","author":"C Liu","year":"2025","unstructured":"Liu C, Yin Q, Wu Z, Li W, Huang J, Chen B, Yang Y, Zheng X, Zeng L, Wang J. Inflammation and immune escape in ovarian cancer: pathways and therapeutic opportunities. J Inflamm Res. 2025;18:895\u2013909.","journal-title":"J Inflamm Res"},{"issue":"1","key":"1948_CR239","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1186\/s12967-025-06583-3","volume":"23","author":"S Bakrim","year":"2025","unstructured":"Bakrim S, Fessikh ME, Elhrech H, Omari NE, Amanullah M, Ming LC, Moshawih S, Bouyahya A. Targeting inflammation in cancer therapy: from mechanistic insights to emerging therapeutic approaches. J Transl Med. 2025;23(1):588.","journal-title":"J Transl Med"},{"key":"1948_CR240","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3389\/fonc.2017.00024","volume":"7","author":"T Worzfeld","year":"2017","unstructured":"Worzfeld T, Pogge E, von Strandmann M, Huber T, Adhikary U, Wagner S, Reinartz, M\u00fcller R. The unique molecular and cellular microenvironment of ovarian cancer. Front Oncol. 2017;7:24.","journal-title":"Front Oncol"},{"issue":"5","key":"1948_CR241","first-page":"3044","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, Ladwa R, O\u2019Byrne K, Kulasinghe A. Immune Checkp Inhibitors Cancer Therapy Curr Oncol. 2022;29(5):3044\u201360.","journal-title":"Immune Checkp Inhibitors Cancer Therapy Curr Oncol"},{"issue":"24","key":"1948_CR242","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.21037\/atm-20-4499","volume":"8","author":"NC Demircan","year":"2020","unstructured":"Demircan NC, Boussios S, Tasci T, \u00d6zt\u00fcrk MA. Current and future immunotherapy approaches in ovarian cancer. Ann Transl Med. 2020;8(24):1714.","journal-title":"Ann Transl Med"},{"issue":"16","key":"1948_CR243","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1200\/JCO.19.02059","volume":"38","author":"D Zamarin","year":"2020","unstructured":"Zamarin D, Burger RA, Sill MW, Powell DJ Jr., Lankes HA, Feldman MD, Zivanovic O, Gunderson C, Ko E, Mathews C, Sharma S, Hagemann AR, Khleif S, Aghajanian C. Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG oncology study. J Clin Oncol. 2020;38(16):1814\u201323.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1948_CR244","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3892\/ol.2024.14782","volume":"29","author":"X Huang","year":"2025","unstructured":"Huang X, Luo J, Gu L. Efficacy and safety of different angiogenesis inhibitors combined with PARP inhibitors in the treatment of ovarian cancer: A systematic review and meta\u2013analysis. Oncol Lett. 2025;29(1):36.","journal-title":"Oncol Lett"},{"issue":"2","key":"1948_CR245","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41401-022-00953-z","volume":"44","author":"J-j Ni","year":"2023","unstructured":"Ni J-j, Zhang Z-z, Ge M-j, Chen J-y, Zhuo W. Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights. Acta Pharmacol Sin. 2023;44(2):288\u2013307.","journal-title":"Acta Pharmacol Sin"},{"issue":"31","key":"1948_CR246","doi-asserted-by":"publisher","first-page":"12837","DOI":"10.1073\/pnas.0703342104","volume":"104","author":"K Odunsi","year":"2007","unstructured":"Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman EW, Pan L, Ritter G, Villella J, Thomas B, Rodabaugh K, Lele S, Shrikant P, Old LJ, Gnjatic S. Vaccination with an NY-ESO-1 peptide of HLA class I\/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A. 2007;104(31):12837\u201342.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"1948_CR247","first-page":"3733","volume":"12","author":"EG Hartnett","year":"2020","unstructured":"Hartnett EG, Knight J, Radolec M, Buckanovich RJ, Edwards RP, Vlad AM. Immunotherapy Adv Epithel Ovarian Cancer Cancers. 2020;12(12):3733.","journal-title":"Immunotherapy Adv Epithel Ovarian Cancer Cancers"},{"key":"1948_CR248","doi-asserted-by":"crossref","unstructured":"Pan J, Zeng W, Jia J, Shi Y, Wang D, Dong J, Fang Z, He J, Yang X, Zhang R, He M, Huang M, Fu B, Zhong B, Liu H. A Novel Therapeutic Tumor Vaccine Targeting MUC1 in Combination with PD-L1 Elicits Specific Anti-Tumor Immunity in Mice. Vaccines (Basel). 2022;10(7).","DOI":"10.3390\/vaccines10071092"},{"key":"1948_CR249","doi-asserted-by":"crossref","unstructured":"Kim CG, Sang YB, Lee JH, Chon HJ. Combining cancer vaccines with immunotherapy: establishing a new immunological approach. Int J Mol Sci. 2021;22(15).","DOI":"10.3390\/ijms22158035"},{"issue":"8034","key":"1948_CR250","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/s41586-024-07962-4","volume":"634","author":"B Feng","year":"2024","unstructured":"Feng B, Bai Z, Zhou X, Zhao Y, Xie Y-Q, Huang X, Liu Y, Enbar T, Li R, Wang Y, Gao M, Bonati L, Peng M-W, Li W, Tao B, Charmoy M, Held W, Melenhorst JJ, Fan R, Guo Y, et al. The type 2 cytokine Fc\u2013IL-4 revitalizes exhausted CD8\u2009+\u2009T cells against cancer. Nature. 2024;634(8034):712\u201320.","journal-title":"Nature"},{"issue":"9","key":"1948_CR251","doi-asserted-by":"publisher","first-page":"e70020","DOI":"10.1002\/ctm2.70020","volume":"14","author":"A Alsalloum","year":"2024","unstructured":"Alsalloum A, Shevchenko JA, Sennikov S. NY-ESO-1 antigen: a promising frontier in cancer immunotherapy. Clin Transl Med. 2024;14(9):e70020.","journal-title":"Clin Transl Med"},{"issue":"3\u20134","key":"1948_CR252","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.prostaglandins.2010.08.001","volume":"93","author":"WZ Li","year":"2010","unstructured":"Li WZ, Huo QJ, Wang XY, Xu F. Inhibitive effect of celecoxib on the adhesion and invasion of human tongue squamous carcinoma cells to extracellular matrix via down regulation of MMP-2 expression. Prostaglandins Other Lipid Mediat. 2010;93(3\u20134):113\u20139.","journal-title":"Prostaglandins Other Lipid Mediat"},{"issue":"6","key":"1948_CR253","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.3892\/mmr.2014.2131","volume":"9","author":"Y Lin","year":"2014","unstructured":"Lin Y, Cui M, Xu T, Yu W, Zhang L. Silencing of cyclooxygenase-2 inhibits the growth, invasion and migration of ovarian cancer cells. Mol Med Rep. 2014;9(6):2499\u2013504.","journal-title":"Mol Med Rep"},{"issue":"1","key":"1948_CR254","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4143\/crt.2014.46.1.81","volume":"46","author":"HJ Kim","year":"2014","unstructured":"Kim HJ, Yim GW, Nam EJ, Kim YT. Synergistic effect of COX-2 inhibitor on paclitaxel-induced apoptosis in the human ovarian cancer cell line OVCAR-3. Cancer Res Treat. 2014;46(1):81\u201392.","journal-title":"Cancer Res Treat"},{"issue":"26","key":"1948_CR255","doi-asserted-by":"publisher","first-page":"39582","DOI":"10.18632\/oncotarget.8659","volume":"7","author":"A Suri","year":"2016","unstructured":"Suri A, Sheng X, Schuler KM, Zhong Y, Han X, Jones HM, Gehrig PA, Zhou C, Bae-Jump VL. The effect of celecoxib on tumor growth in ovarian cancer cells and a genetically engineered mouse model of serous ovarian cancer. Oncotarget. 2016;7(26):39582\u201394.","journal-title":"Oncotarget"},{"issue":"10","key":"1948_CR256","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1093\/annonc\/mdv309","volume":"26","author":"EM Dijkgraaf","year":"2015","unstructured":"Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Wouters MC, Kenter GG, van Erkel AR, van Poelgeest MI, Nijman HW, van der Hoeven JJ, Welters MJ, van der Burg SH, Kroep JR. A phase I trial combining carboplatin\/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-\u03b12b in patients with recurrent epithelial ovarian cancer. Ann Oncol. 2015;26(10):2141\u20139.","journal-title":"Ann Oncol"},{"issue":"23","key":"1948_CR257","doi-asserted-by":"publisher","first-page":"5759","DOI":"10.1158\/1078-0432.CCR-10-1095","volume":"16","author":"Y Guo","year":"2010","unstructured":"Guo Y, Nemeth J, O\u2019Brien C, Susa M, Liu X, Zhang Z, Choy E, Mankin H, Hornicek F, Duan Z. Effects of Siltuximab on the IL-6\u2013Induced signaling pathway in ovarian cancer. Clin Cancer Res. 2010;16(23):5759\u201369.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"1948_CR258","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1158\/1078-0432.CCR-13-2200","volume":"20","author":"E Angevin","year":"2014","unstructured":"Angevin E, Tabernero J, Elez E, Cohen SJ, Bahleda R, van Laethem JL, Ottensmeier C, Lopez-Martin JA, Clive S, Joly F, Ray-Coquard I, Dirix L, Machiels JP, Steven N, Reddy M, Hall B, Puchalski TA, Bandekar R, van de Velde H, Tromp B, et al. A phase I\/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res. 2014;20(8):2192\u2013204.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1948_CR259","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1002\/mc.22325","volume":"55","author":"N Yanaihara","year":"2016","unstructured":"Yanaihara N, Hirata Y, Yamaguchi N, Noguchi Y, Saito M, Nagata C, Takakura S, Yamada K, Okamoto A. Antitumor effects of interleukin-6 (IL-6)\/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary. Mol Carcinog. 2016;55(5):832\u201341.","journal-title":"Mol Carcinog"},{"issue":"2","key":"1948_CR260","doi-asserted-by":"publisher","first-page":"141","DOI":"10.32604\/or.2022.023346","volume":"29","author":"N Hemmat","year":"2021","unstructured":"Hemmat N, Doustvandi MA, Asadzadeh Z, Mokhtarzadeh A, Baradaran B, Baghi HB. Suppression of human papillomavirus type 16 E5 oncoprotein: A promising step in fostering the treatment of cervical cancer. Oncol Res. 2021;29(2):141\u20138.","journal-title":"Oncol Res"},{"issue":"10","key":"1948_CR261","doi-asserted-by":"publisher","first-page":"19265","DOI":"10.3390\/ijms151019265","volume":"15","author":"W Li","year":"2014","unstructured":"Li W, Wan L, Zhai LY, Wang J. Effects of SC-560 in combination with cisplatin or taxol on angiogenesis in human ovarian cancer xenografts. Int J Mol Sci. 2014;15(10):19265\u201380.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1948_CR262","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.3390\/ijms23031432","volume":"23","author":"OR Kolawole","year":"2022","unstructured":"Kolawole OR, Kashfi K. NSAIDs and cancer resolution: new paradigms beyond cyclooxygenase. Int J Mol Sci. 2022;23(3):1432.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1948_CR263","doi-asserted-by":"publisher","first-page":"100536","DOI":"10.1016\/j.esmoop.2022.100536","volume":"7","author":"L Musacchio","year":"2022","unstructured":"Musacchio L, Cicala CM, Camarda F, Ghizzoni V, Giudice E, Carbone MV, Ricci C, Perri MT, Tronconi F, Gentile M, Salutari V, Scambia G, Lorusso D. Combining PARP Inhibition and immune checkpoint Blockade in ovarian cancer patients: a new perspective on the horizon? ESMO Open. 2022;7(4):100536.","journal-title":"ESMO Open"},{"issue":"1","key":"1948_CR264","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12943-023-01925-5","volume":"23","author":"M Chehelgerdi","year":"2024","unstructured":"Chehelgerdi M, Chehelgerdi M, Khorramian-Ghahfarokhi M, Shafieizadeh M, Mahmoudi E, Eskandari F, Rashidi M, Arshi A, Mokhtari-Farsani A. Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy. Mol Cancer. 2024;23(1):9.","journal-title":"Mol Cancer"},{"issue":"10","key":"1948_CR265","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.3390\/cancers17101637","volume":"17","author":"F Xue","year":"2025","unstructured":"Xue F, Yang H, Xu P, Zhang S, Britzen-Laurent N, Bao L-L, Gr\u00fctzmann R, Krautz C, Pilarsky C. CRISPR\/Cas9 Screening Highlights PFKFB3 Gene as a Major Contributor to 5-Fluorouracil Resistance in Esophageal Cancer. Cancers. 2025;17(10):1637.","journal-title":"Cancers"},{"issue":"4","key":"1948_CR266","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3390\/cancers14040947","volume":"14","author":"S Rafii","year":"2022","unstructured":"Rafii S, Tashkandi E, Bukhari N, Al-Shamsi HO. Current status of CRISPR\/Cas9 application in clinical cancer research: opportunities and challenges. Cancers. 2022;14(4):947.","journal-title":"Cancers"},{"issue":"2","key":"1948_CR267","first-page":"652","volume":"8","author":"N Azadbakht","year":"2021","unstructured":"Azadbakht N, Doosti A, Jami M-S. Editing of LINC00511 gene with a new CRISPR\/Cas9 technique and evaluation of its effects on lung cancer cell line. J Jiroft Univ Med Sci. 2021;8(2):652\u201363.","journal-title":"J Jiroft Univ Med Sci"},{"key":"1948_CR268","doi-asserted-by":"publisher","first-page":"1037124","DOI":"10.3389\/fimmu.2022.1037124","volume":"13","author":"Y Wei","year":"2022","unstructured":"Wei Y, Zhao Z, Ma X. Description of CRISPR-Cas9 development and its prospects in human papillomavirus-driven cancer treatment. Front Immunol. 2022;13:1037124.","journal-title":"Front Immunol"},{"issue":"1","key":"1948_CR269","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12985-025-02783-x","volume":"22","author":"AZ Kermanshahi","year":"2025","unstructured":"Kermanshahi AZ, Ebrahimi F, Taherpoor A, Eslami N, Baghi HB. HPV-driven cancers: a looming threat and the potential of CRISPR\/Cas9 for targeted therapy. Virol J. 2025;22(1):156.","journal-title":"Virol J"},{"issue":"1","key":"1948_CR270","first-page":"612823","volume":"2014","author":"Z Hu","year":"2014","unstructured":"Hu Z, Yu L, Zhu D, Ding W, Wang X, Zhang C, Wang L, Jiang X, Shen H, He D. Disruption of HPV16-E7 by CRISPR\/Cas system induces apoptosis and growth Inhibition in HPV16 positive human cervical cancer cells. Biomed Res Int. 2014;2014(1):612823.","journal-title":"Biomed Res Int"},{"issue":"2","key":"1948_CR271","first-page":"2197","volume":"17","author":"T Yoshiba","year":"2019","unstructured":"Yoshiba T, Saga Y, Urabe M, Uchibori R, Matsubara S, Fujiwara H, Mizukami H. CRISPR\/Cas9-mediated cervical cancer treatment targeting human papillomavirus E6. Oncol Lett. 2019;17(2):2197\u2013206.","journal-title":"Oncol Lett"},{"key":"1948_CR272","doi-asserted-by":"publisher","first-page":"108861","DOI":"10.1016\/j.bioelechem.2024.108861","volume":"162","author":"HV Nguyen","year":"2025","unstructured":"Nguyen HV, Hwang S, Lee SW, Jin E, Lee M-H. Detection of HPV 16 and 18 L1 genes by a nucleic acid amplification-free electrochemical biosensor powered by CRISPR\/Cas9. Bioelectrochemistry. 2025;162:108861.","journal-title":"Bioelectrochemistry"},{"key":"1948_CR273","unstructured":"Hemmat N. Evaluation of SiRNA function on human papillomavirus E5 and epidermal growth factor receptor gene expression in CaSki cells. Tabriz University of Medical Sciences, Faculty of Medicine; 2020."},{"key":"1948_CR274","doi-asserted-by":"publisher","first-page":"107327482513364","DOI":"10.1177\/10732748251336415","volume":"32","author":"RU Hakim","year":"2025","unstructured":"Hakim RU, Amin T, Ul Islam SMB. Advances and challenges in cervical cancer: from molecular mechanisms and global epidemiology to innovative therapies and prevention strategies. Cancer Control. 2025;32:10732748251336415.","journal-title":"Cancer Control"},{"issue":"1","key":"1948_CR275","doi-asserted-by":"publisher","first-page":"100211","DOI":"10.1016\/j.xgen.2022.100211","volume":"3","author":"J Fan","year":"2023","unstructured":"Fan J, Fu Y, Peng W, Li X, Shen Y, Guo E, Lu F, Zhou S, Liu S, Yang B, Qin X, Hu D, Xiao R, Li X, Yang S, Yuan C, Shu Y, Huang H, Wan T, Pi Y, et al. Multi-omics characterization of silent and productive HPV integration in cervical cancer. Cell Genom. 2023;3(1):100211.","journal-title":"Cell Genom"},{"key":"1948_CR276","doi-asserted-by":"publisher","first-page":"5958429","DOI":"10.1155\/2017\/5958429","volume":"2017","author":"SS Chung","year":"2017","unstructured":"Chung SS, Wu Y, Okobi Q, Adekoya D, Atefi M, Clarke O, Dutta P, Vadgama JV. Proinflammatory Cytokines IL-6 and TNF-\u03b1 Increased Telomerase Activity through NF-\u03baB\/STAT1\/STAT3 Activation, and Withaferin A Inhibited the Signaling in Colorectal Cancer Cells. Mediators Inflamm. 2017;2017:5958429.","journal-title":"Mediators Inflamm"},{"issue":"7","key":"1948_CR277","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.cell.2024.02.041","volume":"187","author":"A Passaro","year":"2024","unstructured":"Passaro A, Al Bakir M, Hamilton EG, Diehn M, Andr\u00e9 F, Roy-Chowdhuri S, Mountzios G, Wistuba II, Swanton C, Peters S. Cancer biomarkers: emerging trends and clinical implications for personalized treatment. Cell. 2024;187(7):1617\u201335.","journal-title":"Cell"},{"key":"1948_CR278","doi-asserted-by":"crossref","unstructured":"Colombo I, Karakasis K, Suku S, Oza AM. Chasing immune checkpoint inhibitors in ovarian cancer: novel combinations and biomarker discovery. Cancers (Basel). 2023;15(12).","DOI":"10.3390\/cancers15123220"},{"key":"1948_CR279","doi-asserted-by":"crossref","unstructured":"Paithankar V, Devnani D, Nimburkar TA. A review Article on AI-guided discovery of novel Anti-inflammatory agents for cancer therapy: a new era in drug development. Intell Hosp. 2025;100007.","DOI":"10.1016\/j.inhs.2025.100007"},{"issue":"10","key":"1948_CR280","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1080\/14760584.2016.1176533","volume":"15","author":"P Vici","year":"2016","unstructured":"Vici P, Pizzuti L, Mariani L, Zampa G, Santini D, Di Lauro L, Gamucci T, Natoli C, Marchetti P, Barba M, Maugeri-Sacc\u00e0 M, Sergi D, Tomao F, Vizza E, Di Filippo S, Paolini F, Curzio G, Corrado G, Michelotti A, Sanguineti G, et al. Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies. Expert Rev Vaccines. 2016;15(10):1327\u201336.","journal-title":"Expert Rev Vaccines"},{"issue":"2","key":"1948_CR281","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ygyno.2009.09.043","volume":"116","author":"DE Matei","year":"2010","unstructured":"Matei DE, Nephew KP. Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. Gynecol Oncol. 2010;116(2):195\u2013201.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1948_CR282","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41392-024-01953-7","volume":"9","author":"Q Li","year":"2024","unstructured":"Li Q, Geng S, Luo H, Wang W, Mo Y-Q, Luo Q, Wang L, Song G-B, Sheng J-P, Xu B. Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy. Signal Transduct Target Therapy. 2024;9(1):266.","journal-title":"Signal Transduct Target Therapy"},{"key":"1948_CR283","doi-asserted-by":"crossref","unstructured":"Ashrafi GH, Ozdogan M, Cakir MO. Papillomavirus-Induced oncogenesis: bridging molecular mechanisms, diagnostics, and global prevention strategies. Viruses. 2025;17(4).","DOI":"10.3390\/v17040515"},{"issue":"5","key":"1948_CR284","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1080\/01443615.2019.1634030","volume":"40","author":"KS Okunade","year":"2020","unstructured":"Okunade KS. Human papillomavirus and cervical cancer. J Obstet Gynaecol. 2020;40(5):602\u20138.","journal-title":"J Obstet Gynaecol"},{"key":"1948_CR285","doi-asserted-by":"publisher","first-page":"115015","DOI":"10.1016\/j.biopha.2023.115015","volume":"164","author":"M Nigam","year":"2023","unstructured":"Nigam M, Mishra AP, Deb VK, Dimri DB, Tiwari V, Bungau SG, Bungau AF, Radu A-F. Evaluation of the association of chronic inflammation and cancer: Insights and implications. Biomed Pharmacother. 2023;164:115015.","journal-title":"Biomed Pharmacother"},{"key":"1948_CR286","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ctrv.2019.07.001","volume":"78","author":"T Shibata","year":"2019","unstructured":"Shibata T, Lieblong BJ, Sasagawa T, Nakagawa M. The promise of combining cancer vaccine and checkpoint Blockade for treating HPV-related cancer. Cancer Treat Rev. 2019;78:8\u201316.","journal-title":"Cancer Treat Rev"},{"key":"1948_CR287","doi-asserted-by":"crossref","unstructured":"W\u0142oszek E, Krupa K, Skrok E, Budzik MP, Depta\u0142a A, Badowska-Kozakiewicz A. HPV and cervical Cancer-Biology, Prevention, and treatment updates. Curr Oncol. 2025;32(3).","DOI":"10.3390\/curroncol32030122"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-025-01948-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01948-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01948-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T14:04:08Z","timestamp":1769177048000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13048-025-01948-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":286,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1948"],"URL":"https:\/\/doi.org\/10.1186\/s13048-025-01948-0","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"4 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}